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CHAPTER I. INTRODUCTION 
 
STAPHYLOCOCCUS AUREUS IS A SIGNIFICANT THREAT TO PUBLIC HEALTH 
Staphylococcus aureus is a Gram-positive bacterial pathogen that 
asymptomatically colonizes the anterior nares of approximately a third of the population 
(1). Upon breaching host defenses, S. aureus is capable of causing a wide range of 
diseases, ranging from superficial skin and soft tissue infections (SSTIs) to invasive 
diseases with considerable mortality. S. aureus is a leading pathogen associated with 
invasive, life-threatening blood stream infections and ventilator-associated pneumonia (2-
4). Together disease caused by S. aureus results in approximately 40,000 deaths annually 
in the United States alone (5-8).  
The emergence of antimicrobial resistance is a significant public health threat. It 
is currently estimated that at least half of S. aureus clinical isolates are resistant to 
methicillin, and furthermore resistance to last line antibiotics such as vancomycin is on 
the rise (5, 6, 9-12). Taken together, the therapeutic options available for treatment of 
staphylococcal infections have decreased substantially such that The Centers for Disease 
Control and Prevention categorized methicillin resistant S. aureus (MRSA) as a “Serious 
Threat” to the United States (13). Importantly, MRSA is responsible for approximately 
50% of deaths due to any antibiotic resistant organism in the United States (13). There is 
a dire need for a further understanding the pathogenesis of this organism in an effort to 
identify novel therapeutic targets. 
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PROPIONIBACTERIUM ACNES IS A HUGE HEALTHCARE BURDEN 
Propionibacterium acnes, the causative agent of acne, is a Gram-positive 
bacterium that colonizes virtually the entire population. Over 90% of the world’s 
population will suffer from P. acnes infection over the course of their lifetime (14-16). 
Although not life threatening, P. acnes leads to the development of disfiguring lesions 
that have a tremendous impact on the individual. Because of this, acne poses significant 
social and economic burdens. Acne is associated with low self-esteem, poor work and 
school performance, and higher unemployment rates (14, 17). Direct costs due to acne are 
estimated to exceed $4B each year (14, 18). In addition, there is a dramatic effect on 
quality of life for patients suffering from acne, which has been quantified monetarily to 
exceed $12B a year (18).  
Although there is a vast array of treatments for acne, effectiveness and side effects 
limit much of their use. Antibiotic resistance in P. acnes is a growing threat and it is 
estimated that 50% of P. acnes isolates are resistant to current therapeutics (19). In 
addition, current treatments have significant drawbacks due to their often extensive side 
effect profiles. Oral isotretinoin, the most effective treatment for acne, has the most 
extensive side effects, including joint pain, headaches, and depression (20). In addition, 
isotretinoin is a strong teratogen, preventing use in women of reproductive age, one of the 
largest populations affected by acne (20). Given the incredible social and economic 
burden caused by acne, it is clear that new therapeutic strategies for the treatment of acne 
are urgently needed. 
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HEME HOMEOSTASIS IS ESSENTIAL TO BACTERIAL DISEASE 
Bacteria require the essential nutrient heme to colonize the vertebrate host (21-
24). Heme serves as a cofactor for numerous processes within the cell, as well as an iron 
source during infection. The heme requirement can be satisfied by two mechanisms: 
importing exogenous heme through dedicated machinery or synthesizing endogenous 
heme de novo from metabolic precursors. Both acquisition and synthesis of heme are 
required for S. aureus to cause disease (21, 25-27). 
 
S. AUREUS ACQUIRES HEME FROM THE HOST 
Within the human host, S. aureus is in a constant battle to acquire nutrient metals 
(28). Humans have developed intricate defense mechanisms to sequester nutrients from 
invading pathogens in a process termed “nutritional immunity” (12). S. aureus requires 
exogenous heme as an iron source in order to successfully cause disease; however, the 
majority of heme is complexed to hemoglobin within the host. Hemoglobin is stored 
within red blood cells (RBCs), providing yet another layer of defense that S. aureus must 
overcome to gain access to this essential nutrient. S. aureus has developed a system to 
overcome this by secreting hemolysins, which lyse RBCs and liberate hemoglobin. The 
iron-regulated surface determinant (Isd) system of S. aureus then extracts and imports 
exogenous heme (27, 29). Intact heme is a required cofactor for cytochromes in the 
electron transport chain, is necessary for catalase in order to detoxify reactive oxygen 
species (ROS), and is also a cofactor for bacterial nitric oxide synthase (bNOS) (22, 30). 
The Isd system can further break down heme to release iron, a required nutrient metal 
(31). 
 4 
GRAM-POSITIVE BACTERIA UTILIZE A UNIQUE HEME BIOSYNTHESIS PATHWAY 
Heme is required by all kingdoms of life. Heme biosynthesis was long thought to 
proceed through a pathway conserved across all species. Therefore, antibacterial 
strategies were not focused on targeting heme biosynthesis due to potential off-target 
effects in humans. However, in the last two years Dailey et al. and Lobo et al. 
independently published reports that the majority of Gram-positive organisms synthesize 
heme through a noncanonical pathway, utilizing three distinct terminal enzymes that 
differ from the classical pathway (32, 33).  
Early heme biosynthesis proceeds through the same mechanism in both the 
classical and noncanonical pathways (Figure 1). However, upon production of 
coproporphyrinogen III (CPGIII) the two pathways diverge. In the classical pathway, 
CPGIII is converted to protoporphyrinogen IX (PPGIX) by HemF/N. PPGIX is then 
converted to protoporphyrin IX (PPIX) through a six electron oxidation catalyzed by 
protoporphyrinogen oxidase (annotated as HemG, HemJ, or HemY). Finally, 
ferrochelatase (HemH) assists in coordinating an iron atom in the porphyrin ring, 
resulting in heme. In organisms that utilize the noncanonical pathway however, CPGIII is 
instead converted to coproporphyrin III (CPIII) by coproporphyrinogen oxidase (HemY), 
followed by coordination of an iron atom by HemH to produce copro-heme. The final 
enzyme, HemQ, was recently discovered and is specific to the noncanonical pathway. 
HemQ catalyzes the decarboxylation of copro-heme to form heme (21, 24, 32-34). 
Although often annotated in a similar fashion, there are two distinct genes that 
encode HemY leading to differences in structure and function, one in each pathway. In 
the classical pathway HemY serves as a protoporphyrinogen oxidase. Interestingly, it has 
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been observed previously that Gram-positive HemY retains unique characteristics, 
making it distinct from the classical HemY. Multiple studies have found that Gram-
positive HemY has the ability to oxidize both PPGIX as well as CPGIII (34-37). 
Importantly, Gram-positive HemY converts CPGIII at a rate 9-fold higher than PPGIX 
(32). Upon further investigation, Dailey et al. found that these are in fact structurally and 
functionally distinct enzymes, which led to the characterization of the noncanonical 
pathway (32). The divergence of the classical and noncanonical pathways has opened the 
door to the exciting possibility of Gram-positive specific therapies targeting the terminal 
steps of heme biosynthesis. 
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Figure 1. Gram-positive heme biosynthesis utilizes a noncanonical pathway.  
Recently it was uncovered that heme biosynthesis in Gram-positive bacteria proceeds through a 
noncanonical pathway (red), as opposed to the classical pathway (blue) utilized by all other organisms (21, 
32, 33). 
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ALTHOUGH REQUIRED, HEME IS TOXIC 
Although required to successfully colonize the host, excess heme is toxic to the 
bacteria. Thus, the ability to sense and respond to increased levels of heme is critical to 
the survival of many Gram-positive pathogens. A major mechanism by which bacteria 
sense and respond to their environment is through the use of two-component systems (38-
41). Two-component systems are present in almost all bacterial genomes (41). A 
prototypical two-component system utilizes a membrane bound sensor histidine kinase to 
sense specific stimuli. Upon activation by a signal, the kinase undergoes 
autophosphorylation. The kinase facilitates phosphotransfer to and therefore activation of 
a cognate response regulator, which induces a desired response. One of the most common 
responses induces is modification of the transcriptional program of the bacteria (38, 40). 
There is significant interest in understanding the specific mechanisms that facilitate two-
component system signal transduction. In addition, despite the thousands of two-
component systems identified, only a handful have known ligands (40, 42, 43). 
S. aureus senses heme through a two-component system, the heme sensor system 
(HssRS). Upon activation, the membrane histidine kinase, HssS, activates the response 
regulator, HssR, which induces the expression of the heme-regulated transporter (hrtAB). 
hrtAB encodes an efflux pump that alleviates heme toxicity (44, 45). The coordinated 
efforts of HssRS and HrtAB enable S. aureus to grow in the presence of high heme 
concentrations. As with the majority of two-component systems, the signal that activates 
the sensor histidine kinase, in this case HssS, remains unknown (Figure 2) (44, 46). 
Previously it has been identified that deletion of components of HssRS affect the 
virulence of the pathogen (46). Determining the mechanisms by which pathogens cope 
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with heme stress will lead to insight into novel therapeutic targets. As heme sensing 
systems are conserved across numerous medically relevant pathogens, this work may be 
applicable to numerous infectious agents. 
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Figure 2. The S. aureus heme detoxification system. 
Heme exposure induces the autophosphorylation of HssS, followed by phosphotransfer to HssR. Upon 
activation, HssR induces the expression of hrtAB to alleviate heme toxicity.  
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HIGH-THROUGHPUT SCREEN (HTS) IDENTIFIES SMALL MOLECULE ACTIVATORS OF THE 
S. AUREUS HEME SENSING SYSTEM 
In order to probe the mechanism of HssRS activation, a high-throughput screen 
(HTS) was previously performed utilizing the Vanderbilt Institute for Chemical Biology 
(VICB) small molecule library, consisting of approximately 160,000 compounds (47). A 
Phrt driven luminescent reporter (phrt.lux) was developed and transformed into S. aureus 
(47, 48). Heme induces robust luminescence in wild-type S. aureus harboring phrt.lux, 
and this response is dependent upon an intact two-component system (Figure 3). Using 
this assay, 250 positive hits were identified. The top 110 hits were subjected to secondary 
and tertiary screens to eliminate molecules that generated non-specific luminescence. 
Positive hits were further selected based on chemical-tractability, lack of offending 
functional groups, and absence of significant biological activity based on SciFinder and 
PubChem searches. Ultimately, twelve lead compounds were identified for further 
interrogation. The small molecules VU0038882 (‘882) and VU0043981 (‘3981) were 
selected for focused follow-up (Figure 3). 
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Figure 3. High throughput screen identifies small molecule activators of HssRS. 
A whole cell bioluminescence assay to identify HssRS activators was used to screen the Vanderbilt 
Institute for Chemical Biology small molecule library of approximately 160,000 compounds. Top hits were 
confirmed in a secondary screen employing the phrt.xylE reporter construct. Lead compounds ‘882 and 
‘3981 were identified for focused follow-up. Figure adapted from Mike et al. (47). 
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‘882 INCREASES ENDOGENOUS HEME BIOSYNTHESIS 
In order to further the understanding of HssRS activation, previous studies have 
utilized molecule ‘882 (47, 49). Mike et al. characterized ‘882 as an HssRS activator and 
identified that ‘882 induces two major phenotypes in bacterial cells. First, ‘882 exhibits 
toxicity toward respiration deficient strains of S. aureus (47). Second, ‘882 activates 
HssRS (47). Upon further interrogation, it was determined that these two phenotypes are 
in fact unrelated (49).  
Mike et al. hypothesized that ‘882 may activate HssRS by increasing endogenous 
heme biosynthesis (47). Upon ‘882-treatment, S. aureus accumulates 15-fold more heme 
than untreated cells. In addition, ‘882 does not activate HssRS in strains lacking an intact 
heme biosynthesis pathway. Importantly, this was the first instance that endogenously 
produced heme was shown to activate HssRS. Taken together, ‘882 was identified as an 
activator of endogenous heme biosynthesis. Despite significant efforts, the authors were 
unable to identify the target of ‘882 (47).  
 
OVERCOMING THE HURDLE OF SMALL MOLECULE TARGET IDENTIFICATION 
Identifying the targets of small molecules is a major obstacle in biomedical 
research (50-52). Phenotypic high-throughput screens utilizing small molecule libraries 
often result in the identification of numerous molecules with unknown targets. Several 
approaches have been successful in identifying intracellular targets of small molecules, 
including overexpression libraries, transposon mutagenesis, and the isolation of 
spontaneous resistance mutants (53-59). However, the strategies do not work in all 
circumstances, thereby requiring a multifaceted approach in order to successfully identify 
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the target of a small molecule. Taken together, creative and novel methods for identifying 
cellular targets of small molecules are often necessary in order to be successful in this 
endeavor. Identifying targets of small molecules has the potential to enable the 
development of novel therapeutics strategies to target infectious diseases. 
 
SKIN AND SOFT TISSUE INFECTIONS (SSTIS) ARE A BURDEN TO SOCIETY 
The skin is the largest organ in the human body and is the first barrier to infection. 
Disruption of this physical blockade allows bacteria to colonize and invade into host 
tissues. Skin and soft tissue infections (SSTIs) represent a group of infections relating to 
the skin and the underlying tissues, including the epidermis, dermis, fascia, and 
underlying fat (9, 15, 60). The most common etiological agents of SSTIs are Gram-
positive bacteria. Specifically, S. aureus and P. acnes are among the most prevalent 
causative agents of SSTI (9, 14, 15, 60). In fact, SSTIs are the most common infectious 
cause of clinic visits in the United States (15). Although the exact prevalence is difficult 
to determine due to the wide variability among disease presentation, it is estimated that 
approximately 10% of hospitalized patients suffer from an SSTI, and SSTIs lead to 
approximately 14.2 million ambulatory care visits in the United States (15). With the 
growing rates of antibiotic resistance, identifying novel strategies to treat SSTIs is of 
paramount importance. Photodynamic therapy (PDT) has gained significant interest as a 
therapeutic strategy to treat SSTIs (16). 
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PHOTODYNAMIC THERAPY (PDT) IS A PROMISING THERAPEUTIC STRATEGY 
The first clinical trial with PDT occurred over 100 years ago, and since then PDT 
has developed to treat a variety of diseases, including neoplasms, inflammatory, and 
infectious diseases (16, 61-65). PDT utilizes a photosensitizer molecule that is activated 
by light, leading to the production of reactive oxygen species (ROS) that results in cell 
death (16).  
Various photosensitizers have been developed, however, the only currently US 
Food and Drug Administration approved photosensitizers are aminolevulinic acid (ALA) 
derivatives, which serve as prodrugs (16). When given to a patient, ALA enters the cell 
and increases the flux through the entire heme biosynthetic pathway (Figure 1). This 
results in increased production of porphyrins, such as PPIX in mammalian cells and CPIII 
in bacterial cells, that serve as photosensitizers within the cell. When used to treat skin 
cancers, the goal of the therapy is to kill human cells. However, the major hurdle facing 
treatment of infectious disease is that ALA targets both human and bacterial cells, leading 
to a large number of unwanted side effects, including itching, edema, and inflammatory 
responses (16, 64). Regardless of the side effects, PDT has become more popular for 
treatment of acne and other SSTIs that are recalcitrant to current antibiotic therapy (16, 
20, 61-63, 66, 67). Identification of new photosensitizers specific to bacteria have the 
ability to greatly advance the use of PDT for the treatment of infectious diseases and the 
recent identification of a Gram-positive specific heme biosynthesis pathway has opened 
the door to bacterial specific PDT strategies. 
Recently, the use of PDT is also expanding beyond SSTIs. Gastrointestinal 
endoscopes have been developed that emit wavelengths that activation porphyrins in 
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patients to detect cancer, and further been interrogated for their ability to treat 
gastrointestinal infections (68, 69). Osteomyelitis and infection of orthopedic devices are 
some of the most common invasive bacterial infections, and many researchers are 
developing PDT strategies to combat these infections (66, 70-75). Applications are being 
developed to treat many other diseases as well, including parasitic, dental, and sinus 
infections (67, 76). Taken together, PDT has the potential to significantly expand the 
treatment of numerous infections. 
 
CONCLUSIONS 
S. aureus and P. acnes are significant healthcare threats. There is an urgent need 
to understand the pathogenesis of these organisms in an effort to identify novel 
therapeutic strategies. Through interrogating heme homeostasis, the work described here 
uncovers pathways and treatment strategies that advance our understanding of the 
pathogenesis of these organisms, and furthermore provides mechanisms by which these 
bacteria may be targeted in an effort to expand the current antibacterial armamentarium. 
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CHAPTER II. FUNCTIONAL CHARACTERIZATION OF A TWO-COMPONENT SYSTEM 
THROUGH USE OF A SUICIDE STRAIN 
 
INTRODUCTION 
The ability to sense and respond to environmental stimuli is essential to bacterial 
survival. The major mechanism through which bacteria sense and respond to their 
environment is through the use of two-component systems (38-41). Two-component 
systems are present in virtually every bacterial species, with certain species encoding up 
to 200 two-component systems (41). A prototypical two-component system consists of a 
membrane bound sensor histidine kinase and a cytoplasmic response regulator. Upon 
stimulation, the histidine kinase undergoes autophosphorylation, followed by 
phosphotransfer to the response regulator. The activated response regulator induces the 
desired response, such as altering transcription of target genes (38, 40). 
Membrane bound histidine kinases generally consist of a homodimer. Each 
subunit contains a sensor domain, a linker domain, and a kinase core domain, although 
many variations on this general structure do exist (38-41). For membrane bound histidine 
kinases, the sensor domain is often extra-cytoplasmic. After receiving the signal, the 
linker domain passes the signal through the membrane into the cytoplasm. The 
mechanism by which the signal is relayed is not well understood (40). The kinase core 
domain consists of multiple sub-domains, including the dimerization and phosphotransfer 
domains. Upon the signal passing through the linker domain, a conserved histidine 
residue found in the dimerization domain undergoes autophosphorylation. 
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Phosphotransfer to the response regulator is then catalyzed by the phosphotransfer 
domain of the histidine kinase. 
Response regulators consist of two major domains. First, the receiver domain 
facilitates the association of the response regulator to the dimerization domain of the 
histidine kinase. The interaction of these two domains is important for specificity of the 
response regulator to its cognate histidine kinase. Despite significant advancements in 
this realm, the specific mechanisms governing many aspects of specificity remain to be 
elucidated (38-40, 77, 78). The phosphate group is then transferred to a conserved 
aspartate residue, resulting in a conformational change that activates the output domain. 
The output domain can induce a wide range of outputs, including DNA-binding, RNA-
binding, protein-binding, or enzymatic activity (40). DNA-binding response regulators 
are diverse, even with significant diversity existing within subfamilies. DNA-binding 
response regulators recognize a wide variety of DNA sequences to alter transcription. 
One of the most well characterized families of response regulators is the OmpR family. 
OmpR response regulators generally form homodimers and bind direct repeat DNA 
sequences (38-40, 44, 46). Typically, the response regulator will regulate transcription of 
target genes as well as the genes encoding the two-component system it belongs to, thus 
increasing signal transduction in response to the environmental cue (38, 79). Despite the 
thousands of two-component systems identified, there is not a full understanding of the 
mechanisms by which the histidine kinase senses and responds to stimuli.  
Another challenge facing the study of two-component systems is identifying the 
specific signals that activate the histidine kinases (40). Only a handful of ligands have 
been identified that directly bind a histidine kinase and activate it, despite having 
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identified thousands of two-component systems (40, 42, 43). In the case of 
transmembrane histidine kinase, the signal is often thought to be extracellular; however, 
recent studies have shown that many two-component systems can sense intracellular 
stimuli or membrane perturbations as well (38, 40, 43, 47). The high diversity in signals 
adds to the difficulty in identifying specific ligands that activate histidine kinases.  
Many methods have been developed to interrogate two-component system 
function. The most common method is to monitor phosphorylation using 32P in vitro (80). 
Histidine kinases undergo autophosphorylation in the presence of ATP, thus the rate of 
autophosphorylation can be interrogated using radio-labeled ATP, gel electrophoresis, 
and autoradiography. This method can be used to interrogate potential ligands, as the 
presence of a ligand increases the rate of autophosphorylation. Approximately one third 
of histidine kinases contain a transmembrane domain (38, 43, 81, 82). In order to 
interrogate transmembrane histidine kinase, two methods are often used. By truncating 
the histidine kinase, researchers study the intracellular domain; however, in this case 
ligands cannot be interrogated. Alternatively, recombinantly expressed histidine kinases 
can be reconstituted within liposomes, or membrane vesicles can be created using strains 
over expressing the histidine kinase (42, 83). The rates of phosphotransfer to the response 
regulator can be measured using similar methods. Despite the limitations, much has been 
learned from utilizing these methodologies. Directed mutagenesis has been used to 
identify residues and domains required for various aspects of two-component system 
function. Significant effort has focused on developing in vivo systems to interrogate two-
component systems, such as using fluorescence resonant energy transfer (FRET). Despite 
this, no widely applicable in vivo system has been successful (80). Taken together, 
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developing tools to interrogate two-component system structure and function will lead to 
significant advancements in our understanding of bacterial responses to environmental 
stimuli. 
Two-component systems are virtually ubiquitous in bacteria, and are absent in 
mammals (43, 84). In addition, altering two-component system function can modulate 
virulence in a number of pathogenic bacteria (42, 46, 85-89). Two-component systems 
regulate a variety of processes, including resistance to antibiotics, attachment to host 
tissues, toxin production, and the response to vertebrate immune systems (90). Taken 
together, there is significant interest in understanding two-component systems to further 
our understanding of bacterial physiology as well as identifying bacterial specific 
therapeutic targets. 
S. aureus is a major human pathogen that is responsible for numerous diseases in 
the vertebrate host (3, 4, 9, 10, 91). S. aureus encodes sixteen two-component systems 
that respond to a wide variety of signals, including antibiotic stress, hypoxia, and quorum 
sensing signals (40, 44, 46). As discussed above, identifying the specific ligands of these 
systems is difficult. Of these sixteen two-component systems, only one has one well 
characterized ligand. The Agr two-component system is activated by the autoinducing 
peptide utilized for quorum sensing (40, 92).  
S. aureus requires proper heme homeostasis to successfully colonize the host. 
Previously, a system that responds to heme in S. aureus was identified (46). When 
exposed to high levels of heme, the two-component system HssRS is activated, which 
induces the expression of hrtAB to alleviate heme toxicity. Previous work has identified 
numerous requirements of HssRS activation (44-47, 49, 93). Specifically, directed 
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mutagenesis has identified numerous residues required for HssRS function, and 
furthermore defined the promoter and direct repeat sequence that the response regulator, 
HssR, binds (44, 47). A complete understanding of HssRS signaling remains to be 
elucidated. 
The ability to sense and respond to heme is critical for pathogenesis, yet the 
mechanism of heme sensing remains unknown. Small molecule ‘882 was identified in a 
high-throughput screen as an activator of staphylococcal HssRS. ‘882 increases 
endogenous heme synthesis (47, 49). Here we report the construction of a Phrt driven 
suicide strain to interrogate HssRS function. Using this unique unbiased genetic selection 
strategy, we have uncovered residues of HssRS and Phrt required for detection of 
exogenous heme and endogenous heme. Further studies will interrogate the functional 
repercussions of these mutations on autophosphorylation, phosphotransfer, and DNA-
binding. Understanding how pathogens cope with heme toxicity will lead to insights into 
potential therapeutic targets. Based upon the conservation of heme sensing systems 
across numerous medically relevant pathogens, this work may provide information for 
understanding and manipulating heme sensing in many infectious agents. 
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METHODS 
 
A version of the following Methods is under review at Nature Chemical Biology 
for inclusion in “Antibacterial photosensitization through activation of 
coproporphyrinogen oxidase.” 
 
Bacterial strains, plasmids and growth conditions 
Cloning was performed in Escherichia coli DH5a (InvitrogenÔ). Strains, 
plasmids, and primers used are described in Table 1, Table 2, and Table 3, respectively. 
All S. aureus strains were grown in tryptic soy broth (TSB) or agar (TSA), E. coli strains 
were grown in lysogeny broth (LB) or agar (LBA). 
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Table 1. Bacterial strains used in Chapter II. 
Bacterial Strain Description Reference  
Wild-type Staphylococcus aureus strain Newman (94) 
DhrtB In-frame deletion of hrtB in Newman background (95) 
RN4220 S. aureus cloning intermediate (96) 
hrtAB::relE S. aureus strain Newman expressing two copies of relE at the hrtAB 
locus 
This study  
DhssRS In-frame deletion of hssRS in Newman background (93) 
 
 
Table 2. Plasmids used in Chapter II. 
Plasmids  Reference  
phrt.XylE  (46) 
pKORI  (97) 
pES006  (47) 
pMS001  This study 
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Table 3. Primers used in Chapter II. 
Primer Name Sequence 
MS001 GGGGACAAGTTTGTACAAAAAAGCAGGCTGATTTGCTTAGGACGTGCTGC 
MS001b GATTTGCTTAGGACGTGCTGC 
MS019 GCGTCTTTACAAGCCACATATGGATTCACTTCTCCCTATTTCTTC 
MS020 GGGAGAAGTGAATCCATATGTGGCTTGTAAAGACGC 
MS006 GGGGACCACTTTGTACAAGAAAGCTGGGTGGCCAACTTAAGCCAGG 
MS006b GGCCAACTTAAGCCAGG 
MS023 GCGGCGCATATGGCGTATTTTCTGGATTTTGACG 
MS024 CGCCGCCATATGGCTTTGGTTCAGAGAATGCG 
R-C4Y-F GCTATGGTGCAATATCTTGTTGTCGATGACGATCC 
R-C4Y-R GGATCGTCATCGACAACAAGATATTGCACCATAGC 
R-L5F-T GCTATGGTGCAATGTTTTGTTGTCGATGACG 
R-L5F-B CGTCATCGACAACAAAACATTGCACCATAGC 
R-A49T-F CAGCGTGTCGATATTACAGTGGTAGATATTATGATGG  
R-A49T-R CCATCATAATATCTACCACTG TAA TAT CGA CAC GCT G 
R-C64Y-F GGACGGCTTTCAATTATATAATACATTAAAAAATGATTATGATATACCAG 
R-C64Y-R CTGGTATATCATAATCATTTTTTAATGTATTATATAATTGAAAGCCGTCC 
R-L84H-T CAGCGCGGGATGCACATAGTGACAAAGAGCG 
R-L84H-B CGCTCTTTGTCACTATGTGCATCCCGCGCTG 
R-G94D-T GCGTTTATAAGCGATACTGACGATTATGTAACC 
R-G94D-B GGTTACATAATCGTCAGTATCGCTTATAAACGC 
R-D97N-F GCGTTTATAAGCGGTACTGACAATTATGTAACCAAACCC 
R-D97N-R GGGTTTGGTTACATAATTGTCAGTACCGCTTATAAACGC 
R-V105F-F  CGATTATGTAACCAAACCCTTTGAGTTTAAGGAACTTATTTTTAGAATTCG 
R-V105F-R CGAATTCTAAAAATAAGTTCCTTAAACTCAAAGGGTTTGGTTACATAATCG 
R-E107K-T CCCTTTGAGGTTAAGAAACTTATTTTTAGAATTCG 
R-E107K-B CGAATTCTAAAAATAAGTTTCTTAACCTCAAAGGG 
R-W179C-F CGTGAACAAATAATAGAAAAAATTTGTGGCTATGATTATGAAGGAGATGAGCG 
R-W179C-R CGCTCATCTCCTTCATAATCATAGCCACAAATTTTTTCTATTATTTGTTCACG 
R-G185V-T GGCTATGATTATGAATGAGATGAGCGAACAG 
R-G185V-B CTGTTCGCTCATCTCATTCATAATCATAGCC 
R-G185E-F GGGCTATGATTATGAAGAAGATGAGCGAACAGTTGACG  
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R-G185E-R CGTCAACTGTTCGCTCATCTTCTTCATAATCATAGCCC 
R-R196L-F CAGTTGACGTTCATATTAAGCTACTACGCCAAAG 
R-R196L-R CTTTGGCGTAGTAGCTTAATATGAACGTCAACTG  
R-G215R-F GCCACACTTACAATTGAAACAGTAAGAAGACAAGGCTATAAGGTGG 
R-G215R-R CCACCTTATAGCCTTGTCTTCTTACTGTTTCAATTGTAAGTGTGGC  
S-R152L-T GCAGTATTTATGCTTCCAGATATTGGAG 
S-R152L-B CTCCAATATCTGGAAGCATAAATACTGC 
S-R201G-T GCTAGCGACCGAAGGCTTAATTGATGGTG 
S-R201G-B CACCATCAATTAAGCCTTCGGTCGCTAGC 
S-R215C-F GGTGATTTTGAAACACCTATCAAACAAACATGCAAAGATGAAATTGGAAC  
S-R215C-R GTTCCAATTTCATCTTTGCATGTTTGTTTGATAGGTGTTTCAAAATCACC 
S-R230G-F CACTTTAATAAGATGGGAGAGTCATTGGG 
S-R230G-R CCCAATGACTCTCCCATCTTATTAAAGTG 
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Construction of a suicide strain 
The suicide strain was constructed by allelic replacement as previously described 
(97). PCR was performed with Phusion DNA Polymerase (Thermo Scientific) unless 
stated otherwise. The genomic context upstream of hrtAB was amplified using primers 
MS0001b and MS019 and the downstream fragment was amplified using primers MS020 
and MS006b. The fragments were fused by PCR SOEing to create an NdeI site between 
the upstream and downstream fragments (98). The 3’ adenosine overhangs were added by 
incubation with ExTaq (TaKaRa) for 20 minutes at 72°C. The resulting product was 
ligated into PCR2.1 according to manufacturer’s instructions (Life Technologies). relE 
was amplified from E. coli DH5α using primers MS023 and MS024. The plasmid and 
PCR products were digested with NdeI (New England Biolabs) and ligated with T4 DNA 
Ligase (New England Biolabs) to insert the toxin gene between upstream and 
downstream fragments. The plasmid DNA was isolated from transformants and a strain 
harboring two copies of relE in the correct orientation was selected for downstream 
applications. Using this plasmid as a template, primers MS001 and MS006 were used to 
amplify the suicide construct. This was inserted into pKORI and allelic exchange was 
performed as previously described (97). 
 
Isolation of spontaneous resistant mutants 
Overnight bacterial cultures of suicide strain or DhrtB were subcultured 1:100 into 
5 mL of TSB and grown for 8 hours. One hundred µL of a 1:40,000 dilution were plated 
on media containing ‘882 (5 to 15 µM) or heme (0.5 or 1 µM). The resistant colonies 
were passaged twice on TSA to ensure resistance was genetically stable, and re-
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challenged by plating on heme or ‘882. The colonies that retained resistance were used 
for downstream analysis. 
 
Sequence analysis 
Strains maintaining resistance were sequenced to determine mutations in the 
hssRS and Phrt regions. The mutations were mapped to a template containing the sequence 
of hrtAB::relE in this region. The mutations were analyzed using Lasergene 13 
(DNASTAR).  
 
Cloning 
The plasmid pMS001 was created by restriction digest of plasmid pES006 
(containing Plgt.hssS-myc and Phrt.xylE) to remove hssS-myc (47). Digested plasmid was 
purified using a Gel Extraction Kit (Qiagen). The sequence for hssR-myc was excised 
from a plasmid previously created and purified (pES008, unpublished). Ligation was 
performed with T4 DNA Ligase (NEB) according to the manufacturer’s instructions, 
creating pMS001. Plasmids were purified from transformants and moved into S. aureus 
through standard protocols. The point mutations were created in pES006 and pMS001 
utilizing Pfu mutagenesis with primers described in Table 3 (99). 
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Promoter activity assay 
Promoter activity assay was performed as previously described (44). Briefly, 
phrtAB.xylE was electroporated into the strains as previously described (47).  
 
Immunoblot for HssR and HssS 
Immunoblots for HssR-myc and HssS-myc were performed in S. aureus strains 
containing pMS001 and pES006 as previously described to determine expression levels 
at a 1:10,000 dilution of the a-myc antibody (47). 
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RESULTS 
 
Construction of a suicide strain 
To interrogate the S. aureus heme sensing system, a suicide strain was employed 
enabling selection of S. aureus strains that are unresponsive to exogenous heme or ’882-
induced endogenous heme synthesis. S. aureus hrtAB was replaced with two copies of the 
gene encoding the Escherichia coli RNA interferase toxin RelE under the control of the 
native hrtAB promoter to inhibit growth upon activation of HssRS (Figure 4a). Dual 
copies of relE were used to avoid selection of toxin-inactivating mutations, thereby 
ensuring selection of strains with mutations in HssRS or Phrt. S. aureus hrtAB::relE 
grows equivalently to WT in the absence of heme or ‘882. Upon HssRS induction by 
heme or ‘882, hrtAB::relE is unable to grow (Figure 4b). A strain lacking the hrtB 
permease (DhrtB) was used to ensure that heme or ‘882 do not induce toxicity from heme 
accumulation at tested concentrations. These results demonstrate that the suicide strain 
may be used to identify suppressor mutants unresponsive to heme or ‘882.  
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Figure 4. Construction of a suicide strain to select strains unresponsive to heme or ‘882. 
(a) To create a Phrt suicide strain, the hrtAB genes were replaced with two copies of the E. coli gene 
encoding the RNA interferase toxin RelE. (b) Upon heme or ‘882 stimulation, toxicity is induced in 
hrtAB::relE. A version of this figure is under review at Nature Chemical Biology for inclusion in 
“Antibacterial photosensitization through activation of coproporphyrinogen oxidase.” 
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Identification of residues required for HssRS and Phrt function 
Isolates of hrtAB::relE exhibiting spontaneous resistance to heme and ‘882 were 
identified. The stability of resistance was ensured through serial passage in plain media 
followed by challenge by heme or ‘882 a second time. Genomic DNA was isolated from 
strains retaining resistance to heme or ‘882 in the hrtAB::relE background. In order to 
identify mutations providing resistance to heme- or ‘882-induced activation of HssRS, 
the hssRS/Phrt locus of resistant strains was sequenced. Approximately 90% of the 
mutations identified in this analysis were in hssRS/Phrt. Mutations were identified 
throughout the hssRS locus and the hrtAB promoter (Figure 5, Figure 6).  
With regards to HssS, mutations were found in almost every domain, suggesting 
that all portions of the histidine kinase are required for function (Figure 5). Interestingly, 
mutations were not identified in the two transmembrane domains, suggesting mutations 
in these regions do not affect function of this particular histidine kinase. Importantly, 
intracellular and extracellular mutations were identified using heme or ‘882, consistent 
with both domains being required for exogenous and endogenous heme sensing. All of 
the mutations identified utilizing heme as an activator, also provided resistance to ‘882 
upon re-challenge, and vice versa (data not shown). These data suggest the mechanism by 
which exogenous and endogenous heme are sensed in S. aureus is through a similar 
mechanism. Future studies will saturate selection of strains resistant to these compounds 
allowing further conclusions to be drawn.  
As expected, HssR mutations were identified in both the receiving and DNA-
binding domains (Figure 5). Mutations in these domains likely affect phospho-acceptance 
from HssS and DNA-binding, however, further studies will need to be performed to 
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confirm this hypothesis. Finally, mutations in Phrt were identified that lie within the 
known direct repeat where HssR is known to bind (44). In addition, mutations outside the 
direct repeat were also identified, suggesting a more complex regulatory network is 
required for Phrt activation. 
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Figure 5. Mutations in HssRS identified in suicide selection. 
(a) Cartoon representation of HssRS structure with domains, adapted from (44, 93). (b) Amino acid 
residues identified in sequencing of hssRS in heme resistant hrtAB::relE isolates. (b) Amino acid residues 
identified in sequencing of hssRS in ‘882 resistant hrtAB::relE isolates. 
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Figure 6. Mutations in Phrt identified in suicide selection. 
The wild-type sequence of the promoter of hrtAB is shown. Nucleic acid residues identified in sequencing 
of Phrt in heme and ‘882 resistant hrtAB::relE isolates are highlighted in red. 
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Verification of the suicide selection to interrogate two-component systems 
To confirm the suicide strain selection identifies mutations altering HssRS 
activation, strains lacking hssR (DhssR) or hssS (DhssS) were complemented in trans with 
a vector expressing hssR or hssS, respectively, harboring the identified mutations. Upon 
stimulation of strains expressing the HssR or HssS mutants, reduced activation was seen 
by both heme and ‘882 in all of the mutants (Figure 7). Importantly, regardless of the 
compound used to select the mutation, all the mutations provided resistance to both 
compounds upon re-challenge. In addition, background levels of activation are reduced in 
the HssR mutant strains, further confirming reduced levels of HssRS signaling in these 
strains (Figure 7). Taken together, these data validate the use of hrtAB::relE selection as 
a valuable tool to interrogate two-component system activation and regulation. 
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Figure 7. Mutations in HssRS affect hrtAB activation. 
S. aureus DhssR or DhssS complemented in trans with a vector expressing hssR or hssS harboring the 
identified mutations were analyzed to determine Phrt activation. Strains resistant to ‘882 or heme exhibit 
decreased activation of Phrt when exposed to heme or ‘882. 
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Mutations in HssRS can decrease protein abundance 
Mutations in HssRS and Phrt may disrupt HssRS function through a variety of 
mechanisms. In order to interrogate the effect of these mutations on HssRS activation, a 
workflow was developed to interrogate and classify the mutations based upon their 
functional effects (Figure 8). Four classes were chosen to categorize the identified 
mutations: (i) altered protein abundance, (ii) decreased autophosphorylation of HssS, (iii) 
decreased phosphotransfer from HssS to HssR, and (iv) decreased DNA-binding by 
HssR. 
In order to begin interrogating these residues, protein expression was measured by 
immunoblot. Of the mutations tested, six mutations in HssR (C4Y, L5F, A49T, E107K, 
G185V, R196L) led to decreased protein abundance, providing a mechanism for how 
these mutations provide resistance in the hrtAB::relE strain (Figure 9). The remaining 
mutations interrogated in this preliminary study were produced to equal levels of WT 
HssS or HssR. Mutations that do not affect protein abundance will be further interrogated 
to determine their effect on autophosphorylation, phosphotransfer, and DNA-binding. 
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Figure 8. Workflow for interrogation of HssRS and Phrt mutations. 
Mutations identified in the selection of hrtAB::relE strains will be classified into: (i) altered protein 
expression, (ii) decreased autophosphorylation of HssS, (iii) decreased phosphotransfer from HssS to HssR, 
and (iv) decreased DNA-binding by HssR. 
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Figure 9. Immunoblots identify mutations disrupting protein expression 
S. aureus DhssR (a) or DhssS (b) complemented in trans with a vector expressing hssR-myc or hssS-myc 
harboring the identified mutations were analyzed by immunoblotting for the Myc tag. Immunoblots were 
performed by Reece Knippel. 
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DISCUSSION 
 
Here we report the construction of a suicide strain selection strategy to interrogate 
two-component system structure and function. Isolation of spontaneous resistant strains 
has identified numerous residues that, when mutated, affect HssRS function. The 
mutations were verified to affect levels of hrtAB activation, and this work has begun to 
dissect the mechanisms through which each mutation affects the function of HssRS. 
Further studies will saturate the selection by identifying more mutations, as well as 
continue to dissect mechanisms by which each mutation affects HssRS function. 
Mutations in HssRS have potential to affect protein abundance, 
autophosphorylation, phosphotransfer from HssS to HssR, or HssR binding DNA (Figure 
8). Despite not having saturated the selection, some insights are becoming clear. Heme- 
and ‘882-resistant strains were identified with mutations in both the extracellular and 
intracellular domains. Furthermore, mutations identified in HssS or HssR using heme or 
‘882 provide resistance to the other compound, suggesting that exogenous and 
endogenous heme may be sensed through a similar mechanism. Upon selecting mutants 
to a point of saturation of this system, a better understanding of the mechanism of heme 
sensing will be uncovered. 
Promoter mutations may also affect HssR binding, thereby decreasing activation 
of Phrt. Consistent with this, mutations were identified within the promoter of hrtAB. As 
discussed in the Introduction to this chapter, HssR binds a direct repeat sequence 
upstream of hrtAB. Previous studies have characterized the HssR binding location by 
sequential shortening of the promoter region (44). Here we report the identification of 
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mutations using the suicide strain in the direct repeat, consistent with previous studies. 
Interestingly, mutations outside this region were also identified, suggesting promoter 
regulation is more complex and therefore likely requires additional factors to ensure 
proper gene expression. Future studies will continue to identify mutations required for 
Phrt activation and interrogate their effect on HssR binding. 
A previous high-throughput screen has identified numerous molecules that 
activate HssRS (47). Identifying targets of small molecules remains a significant 
challenge (50-52). Many approaches have been developed to identify small molecule 
targets, however, each has limitations. In order to successfully identify a target, many 
approaches must be taken. One approach that has proven successful is identification of 
spontaneously resistant strains to small molecules that induce growth arrest (53, 55). 
Genome sequencing of DNA from resistant isolates allows for the identification of 
mutations that providing resistance to the molecule of interest. Many molecules induce 
phenotypes other than growth inhibition. ‘882 induces HssRS activation, and therefore 
could not be used in WT bacteria to identify spontaneous resistant isolates. The Phrt 
driven suicide strain overcomes this obstacle by engineering toxicity when exposed to a 
non-toxic small molecule. The suicide strain has identified mutations providing resistance 
to small molecule activators of HssRS. This suggests that identifying strains lacking 
mutations in hssRS and Phrt can be further subjected to whole genome sequencing to 
identify mutations throughout the genome. This will provide insight into the potential 
target of ‘882, which will be discussed in Chapter III. 
Taken together, this work has generated an unbiased in vivo strategy to interrogate 
the structure and function of HssRS. Importantly, the success of this approach suggests 
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this may be applied to other two-component systems in order to further our understanding 
of this essential bacterial signaling process. Specifically, the suicide strain approach 
allows for unbiased in vivo identification of mutations required for sensing without 
directed mutagenesis. Upon completion of this work, a stronger understanding of heme 
sensing in bacterial pathogens will be uncovered.  
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CHAPTER III. ANTIBACTERIAL PHOTOSENSITIZATION THROUGH ACTIVATION OF 
COPROPORPHYRINOGEN OXIDASE 
 
INTRODUCTION 
 
Skin and soft tissue infections (SSTIs) account for a majority of visits to hospitals 
and clinics in the United States, accounting for approximately 14 million ambulatory care 
visits each year (15). Furthermore, approximately 10% of hospitalized patients suffer 
from an SSTI (15). These infections are typically caused by Gram-positive bacteria. 
Etiological agents include Staphylococcus aureus, Staphylococcus epidermidis, 
Propionibacterium acnes, and Bacillus anthracis, the causative agents of “Staph 
infections,” hospital acquired infections, acne, and cutaneous anthrax, respectively (9, 14, 
15, 60). S. aureus and P. acnes are the most prevalent causative agents of SSTIs (9, 14, 
15, 60). In fact over 90% of the world’s population will suffer from acne over the course 
of their lifetime, leading to annual direct costs of over $3 billion (14-16, 18). The threat 
of these pathogens is compounded by the tremendous rise in antibiotic resistance, 
reducing the efficacy of the existing antibacterial armamentarium (9, 15, 60). Identifying 
new drug targets to treat SSTIs is paramount to enable the development of novel 
therapeutics.  
Heme biosynthesis is conserved across all Kingdoms of life and heme is utilized 
for a diverse range of processes within cells. Until recently, it was thought that the heme 
biosynthesis pathway was conserved across all species, limiting its utility as a potential 
therapeutic target to treat infectious diseases. However, Dailey et al. discovered that 
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Gram-positive bacteria utilize a distinct pathway to synthesize the critical cellular 
cofactor heme (Figure 1a) (32, 33). Specifically, Gram-positive heme biosynthesis 
diverges at the conversion of coproporphyrinogen III (CPGIII) to coproporphyrin III 
(CPIII) through a six-electron oxidation by coproporphyrinogen oxidase (HemY), as 
opposed to being converted to protoporphyrin IX (PPIX) in the classical pathway by a 
distinct series of enzymes (21, 32). The divergence of the heme biosynthesis machinery 
between humans and Gram-positive bacteria provides a unique opportunity for the 
development of new antibiotics targeting this pathway as a strategy to treat infections. 
Small molecule ‘882 was previously identified in a screen for activators of the S. 
aureus heme sensing system two-component system (HssRS) (Figure 13b) (44, 46, 47). 
Upon activation, HssRS induces the expression of the heme-regulated transporter 
(HrtAB) to alleviate heme toxicity (44, 46, 47). HssRS activation is triggered by massive 
accumulation of heme in ‘882-exposed bacteria; however, the mechanism by which ‘882 
activates heme biosynthesis has not been uncovered (47). 
We report here the identification of the cellular target of ‘882, a small molecule 
activator of heme biosynthesis, through the use of a Phrt driven suicide strain. ‘882 
activates coproporphyrinogen oxidase (HemY) from Gram-positive bacteria, an enzyme 
essential for heme biosynthesis. Activation of HemY induces accumulation of the product 
of the reaction, coproporphyrin III (CPIII), a photoreactive molecule of demonstrated 
utility in treating bacterial infections (16, 63, 100). Photodynamic therapy (PDT) utilizes 
a photosensitizing molecule activated by a specific wavelength of light to produce 
reactive oxygen species that leads to cell death (16). The only US Food and Drug 
Administration approved photosensitizers are aminolevulinic acid (ALA) derivatives, 
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which serve as prodrugs through their conversion to porphyrins in the heme biosynthetic 
pathway (16). Utilizing ‘882 to activate HemY, CPIII accumulates in a similar manner, 
inducing photosensitization specifically in Gram-positive bacteria,  and ‘882-PDT 
reduces bacterial burden and tissue ulceration in murine models of SSTI. Thus, small 
molecule activation of HemY represents a promising strategy for the development of 
light-based antimicrobial therapies.  
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METHODS 
 
Bacterial strains and growth conditions  
Cloning was performed in Escherichia coli DH5a (InvitrogenÔ). Strains, 
plasmids, and primers used are described in Table 4, Table 5, Table 6, and Table 7. All 
proteins were expressed using E. coli strain BL21(DE3) pREL (47). All S. aureus and S. 
epidermidis strains were grown in tryptic soy broth (TSB) or agar (TSA), E. coli and B. 
anthracis were grown in lysogeny broth (LB) or agar (LBA), and P. acnes in brain heart 
infusion (BHI) broth or agar unless otherwise stated.  
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Table 4. Bacterial strains used in Chapter III. 
Bacterial Strain Description Reference  
Wild-type Staphylococcus aureus strain Newman (94) 
DhrtB In-frame deletion of hrtB in Newman background (95) 
RN4220 S. aureus cloning intermediate (96) 
hrtAB::relE S. aureus strain Newman expressing two copies of relE at the hrtAB 
locus 
This study  
hemY.T183K S. aureus strain Newman harboring a T183K mutation in HemY This study  
DhemY S. aureus strain Newman harboring a transposon interrupting hemY 
expression 
This study  
DhssRS In-frame deletion of hssRS in Newman background (93) 
Staphylococcus epidermidis Strain NRS6 BEI  
Bacillus anthracis Strain Sterne (101) 
Propionibacterium acnes ATCCÒ 6919Ô ATCC 
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Table 5. Expression constructs used in Chapter III. 
Protein Expression Vector Reference  
Wild-type Staphylococcus aureus HemY pET15b This study  
T183K S. aureus HemY pET15b This study  
N186F S. aureus HemY pET15b This study  
N186Y S. aureus HemY pET15b This study  
Y171A S. aureus HemY pET15b This study  
D450Y S. aureus HemY pET15b This study  
F187W S. aureus HemY pET15b This study  
F184A S. aureus HemY pET15b This study  
M167F S. aureus HemY pET15b This study  
V146M S. aureus HemY pET15b This study  
Bacillus subtilis HemY pTrcHisA (34) 
Homo sapiens HemY pTrcHisB (102) 
Propionibacterium acnes HemY pTrcHisA (34) 
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Table 6. Plasmids used in Chapter III. 
Plasmids  Reference  
phrt.xylE  (46) 
pKORI  (97) 
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Table 7. Primers used in Chapter III. 
Primer Name Sequence 
SA_hemY_T183K_T AGTTTGATGAGTACGTTTCCTAATTTTAAAG 
SA_hemY_T183K_B CTTTAAAATTAGGAAACGTACTCATCAAACT 
N186Y_T_NWMN1723 GTTTGATGAGTACGTTTCCTTATTTTAAAGAAAAAGAAGAGGC 
N186Y_B_NWMN1723 GCCTCTTCTTTTTCTTTAAAATAAGGAAACGTACTCATCAAAC 
N186F_T_NWMN1723 GTTTGATGAGTACGTTTCCTTTTTTTAAAGAAAAAGAAGAGGC 
N186F_B_NWMN1723 GCCTCTTCTTTTTCTTTAAAAAAAGGAAACGTACTCATCAAAC 
SA_Y171A_T CCTTTAATGGGTGGTATTGCTGGTACCGATATTG 
SA_Y171A_B CAATATCGGTACCAGCAATACCACCCATTAAAGG 
SA_D450Y_T GCGGTTGGACTACCTTATTGTATTACGCAAGG 
SA_D450Y_B CCTTGCGTAATACAATAAGGTAGTCCAACCGC 
SA_F187W_T GAGTACGTTTCCTAATTGGAAAGAAAAAGAAGAGGCATTCGG 
SA_F187W_B CCGAATGCCTCTTCTTTTTCTTTCCAATTAGGAAACGTACTC 
SA_F184A_T GTTTGATGAGTACGGCTCCTAATTTTAAAGAAAAAGAAGAGGC 
SA_F184A_B GCCTCTTCTTTTTCTTTAAAATTAGGAGCCGTACTCATCAAAC 
SA_M167F_T GAGAATTTAATAGAGCCTTTATTTGGTGGTATTTATGG 
SA_M167F_B CCATAAATACCACCAAATAAAGGCTCTATTAAATTCTC 
SA_V146M_T GGATGGTGACATTTCTATGGGTGCATTTTTCAGAGC 
SA_V146M_B GCTCTGAAAAATGCACCCATAGAAATGTCACCATCC 
MS001 GGGGACAAGTTTGTACAAAAAAGCAGGCTGATTTGCTTAGGACGTGCTGC 
MS001b GATTTGCTTAGGACGTGCTGC 
MS019 GCGTCTTTACAAGCCACATATGGATTCACTTCTCCCTATTTCTTC 
MS020 GGGAGAAGTGAATCCATATGTGGCTTGTAAAGACGC 
MS006 GGGGACCACTTTGTACAAGAAAGCTGGGTGGCCAACTTAAGCCAGG 
MS006b GGCCAACTTAAGCCAGG 
MS023 GCGGCGCATATGGCGTATTTTCTGGATTTTGACG 
MS024 CGCCGCCATATGGCTTTGGTTCAGAGAATGCG 
pet15_hemYF1 GCGGCAGCCATATGGTGACTAAATCAGTGGCTATTATAG 
pet15_hemYF2 GCGGCAGCCATATGCTAGTGACTAAATCAGTGGCTATTATAG 
pet15_hemYR GCTTTGTTAGCAGCCGTTACAACTCTGCGATTACTTC 
pKOR1_hemY_FattB GGGGACAAGTTTGTACAAAAAAGCAGGCTGTGACTAAATCAGTGGCTATTATAG 
pKOR1_hemY_RattB GGGGACCACTTTGTACAAGAAAGCTGGGTTTACAACTCTGCGATTACTTC 
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Strain construction 
S. aureus strain hemY::ermC was described previously and the hemY::ermC allele 
was transduced into strain Newman using the F-85 bacteriophage (29, 103). To create an 
S. aureus strain harboring the T183K mutation in HemY, hemY was amplified from the 
point mutant isolated in the suicide selection using primers pKORI_hemY_FattB and 
pKORI_hemY_RattB. This construct was moved into pKORI and allelic replacement 
was utilized as previously described (97).  
 
Suicide strain selection 
Overnight bacterial cultures of suicide strain or DhrtB were subcultured 1:100 into 
5 mL of TSB and grown for 8 hours. One hundred µL of a 1:40,000 dilution were plated 
on media containing ‘882 (5 to 15 µM). The resistant colonies were passaged twice on 
TSA to ensure resistance was genetically stable, and re-challenged by plating on heme or 
‘882. The colonies that retained resistance to ‘882 but were sensitive to heme were used 
for downstream analysis. 
 
Genome sequencing and analysis 
Genomic DNA was isolated from mutant strains using the Wizard® Genomic Kit 
(Promega) and sequenced to identify mutations in hssRS/Phrt/relErelE. Strains containing 
mutations in this locus were eliminated from subsequent analyses. The genomes from 
strains lacking mutation in this locus were sequenced by Perkin Elmer on the MiSeq 
Platform. 
 51 
Whole genome sequencing analysis was automated with a tool written by Pedro 
Teixeira in the Python programming language. The input files were the Newman genome 
(.fas) and the mutations file (.csv). The program iterates through each mutation 
determining the mutation type and resultant amino acid change if applicable. The input 
.csv is preprocessed to combine proximal mutations in the same strain as both must be 
considered due to their combined codon effect. The script also includes options to specify 
the organism ID, the base pair radius around the mutation to use for genome matching, an 
e-value threshold for allowable search results, and a customizable delimiter character for 
visualization. The program takes into account both strand directions when searching to 
ensure complete coverage as well as potential missed search matches at the edges of the 
genome. All mutations are classified based on their effect – silent, substitution, frame 
shift, truncation, or deletion. 
The Bacterial, Archaeal and Plant Plastid Code (transl_table=11) was used as our 
translation table, more information can be found at 
http://www.ncbi.nlm.nih.gov/Taxonomy/Utils/wprintgc.cgi. 
Mutations in non-coding regions or that produced silent mutations in the amino 
acid sequence were removed. Mutations were compared to a control suicide strain not 
subjected to selection to eliminate mutations present in the parent strain. The genes 
identified in this analysis were re-sequenced in the relevant strain to confirm the presence 
of the mutation. 
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Heme precursor quantification 
Cells were grown in TSB overnight in the presence or absence of 40 µM ‘882. 
The cells were pelleted and lysed as previously described (47). PBG was quantified from 
lysate as previously described (104). For HPLC analysis, protoplast lysates were 
incubated with Dianon HP20 beads for 1 hour at 4°C. Hydrophobic molecules were 
eluted from the beads with 3 mL of acetone. The samples were protected from light. The 
hydrophobic molecules were concentrated in vacuo for 24 hours at room temperature. 
The samples were resuspended in 200 µL 1:1 water:acetonitrile with 0.1% trifluoroacetic 
acid. High performance liquid chromatography was performed as previously described 
(105). Absorbance was measured at a wavelength of 400 nm to identify heme precursor 
molecule peaks. The fractions corresponding to the retention time of CPIII and heme 
standards were collected and lyophilized. The lyophilized fractions were resuspended in 
100 µL 1:1 water:acetonitrile and analyzed by liquid chromatography tandem mass 
spectrometry as previously described (105). HPLC and mass spectrometry was performed 
by Lisa Lojek. 
 
Promoter activity assay 
Promoter activity assay was performed as previously described (44). Briefly, 
phrtAB.xylE was electorporated into the strain hemY.T183K. The other strains used have 
been previously described (47). Overnight cultures were diluted 1:100 into TSB 
supplemented with 10 µg/mL chloramphenicol under the following conditions: vehicle 
(DMSO), 1 µM heme, or 10 µM ‘882. Cells were grown for 6 hours and assayed as 
previously described (46). The experiment was performed in triplicate on three separate 
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days (n=9). Data are presented as mean ± SEM. Student’s t-test was performed to 
determine significance. 
 
S. aureus HemY expression construct 
S. aureus HemY was amplified from either Newman or the suicide strain resistant 
to ‘882 containing the T183K mutation using primers pET15_hemYF1 and 
pET15_hemYR and inserted into pET15b using the Gibson Assembly® Cloning Kit 
(New England Biolabs). The point mutations in hemY were created utilizing Pfu 
mutagenesis with primers described in Table 7 (99). 
 
Enzyme expression and purification 
The plasmids described in Table 5 were transformed into BL21(DE3) pREL. An 
overnight of a strain harboring each HemY expression construct were diluted 1:100 into 
Terrific Broth (Fisher Scientific) supplemented with the appropriate antibiotics and 10 
µg/mL riboflavin. Cells containing H. sapiens HemY were grown at 37°C overnight. The 
cells containing S. aureus and P. acnes HemY were grown at 37°C until they reached an 
OD600 of 0.7, induced with 0.1 mM IPTG, and grown at 30°C overnight. The cells 
containing B. subtilis HemY were grown at 37°C until they reached an OD600 of 0.7, 
induced with 0.1 mM IPTG, and grown for 5 hours 37°C. The cells were washed with 
PBS and stored at -80°C until protein was harvested. The cells were resuspended in lysis 
buffer (50 mM Tris-MOPS, pH 8.0, 0.1 M potassium chloride, and 1% sodium cholate 
hydrate supplemented with 1 mg/mL lysozyme and one Pierce Protease Inhibitor Tablet 
(Thermo Scientific)), homogenized using a Dounce homogenizer, and passed through an 
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EmulsiFlex (Avestin) four times. Lysate was centrifuged at 40,000 x g for one hour and 
filtered with a 0.22 µM filter. 
S. aureus, P. acnes, and H. sapiens HemY were purified utilizing HisPur Cobalt 
Superflow Agarose (Thermo Scientific). The lysate was mixed with agarose and 
incubated at 4°C with rotating for 30 minutes. The lysate and beads were poured into a 
gravity column followed by washing with 10 column volumes of 5 mM imidazole in the 
lysis buffer. Proteins were eluted with 250 mM imidazole in lysis buffer in 5 column 
volumes. B. subtilis protein was purified on an AKTA FPLC (GE Healthcare Life 
Sciences) with a linear gradient from 0 mM to 500 mM imidazole in lysis buffer. 
Glycerol was added to 10% total volume and protein was aliquoted and stored at -80°C. 
A fresh aliquot was used each day for assays. 
All purified enzymes were analyzed by SDS-PAGE and tested for activity to 
verify purity (Figure 10). 
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Figure 10. Purity of HemY used in biochemical assays.  
After purification, each HemY was analyzed by SDS-PAGE to verify purity. 
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HemY activity assay 
Purified HemY was assayed as previously described (106). The reactions were 
performed in 300 µL volume and incubated at room temperature for ten minutes before 
initiating the reaction. Reactions were monitored using a Cytation 5 (BioTek), and 
performed at least twice in triplicate. KM and Vmax values were determined by fitting data 
using the Michaelis-Menten equation in Prism (GraphPad) using 10.8 µg protein in each 
reaction. AC150 and activation (%) values were determined using Response vs. 
Log(substrate) in Prism (GraphPad). For S. aureus and H. sapiens, 10.8 µg of protein was 
used to determine the AC150. For B. anthracis and P. acnes, 5.4 µg of protein was used to 
determine the AC150 to keep reactions in the linear range of the instrument. Data are 
represented as mean ± SEM. 
 
‘882-PAL labeling and protein detection 
Overnight cultures of WT and DhemY in TSB supplemented with 1 µM heme 
were subcultured 1:50 into TSB supplemented with 1 µM heme and grown for 3 hours at 
37°C. The cells were washed in PBS and resuspended in TSM (50 mM Tris-HCl pH 7.5, 
0.5M sucrose, 10 mM MgCl2) with 100 µg/mL lysostaphin and incubated at 37°C for 30 
minutes. The protoplasts were pelleted by centrifugation at 20,000 x g for 20 minutes, 
washed once with TSM and resuspended in lysis buffer described above. The samples 
were sonicated three times at 80% for ten seconds while on ice. Cell debris was pelleted 
by centrifugation at 20,000 x g for 20 minutes.  
The photolabeling and click reaction were performed similarly to what was 
previously described (107).The supernatant was diluted to 1 mg/mL, and ‘882-PAL was 
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added to 10 µM, incubated at room temperature for 2 hours on a rotating mixer in the 
dark, and exposed to UV light for 6 minutes (Deep Dome Lamp Fixture, Zoo Med 
Laboratories, Inc.). The samples were then diluted 1:14 in lysis buffer and reconcentrated 
to 1 mg/mL using an Amicon Ultra Centrifugal Filter Unit (Millipore) with a 3 kDa 
cutoff. CuSO4, tris(3-hydroxypropyltriazolyl-methyl)amine (THPTA), sodium ascorbate, 
and biotin-azide were added to concentrations of 200, 200, 400 , and 50 µM, respectively, 
incubated for 2 hours on a rotating mixer in the dark, diluted and reconcentrated as 
before. The samples were separated on 15% SDS-PAGE gels and transferred to a 
nitrocellulose membrane using a Trans-Blot Turbo (BioRad) according to manufacturer’s 
instructions. The membranes were stained with Ponceau S Solution (Sigma), imaged, and 
destained according to manufacturer’s instructions. The membranes were blocked 
overnight at 4°C in PBS with 5% dry non-fat milk on a rocker, stained with IRDye 
800CW Streptavidin (LI-COR) in PBS with 4% dry non-fat and 0.1% Tween-20 for two 
hours at room temperature on a rocker, washed three times with PBS with 0.1% Tween-
20 for 5 minutes, and two times with PBS for five minutes. The membranes were imaged 
using an Odyssey infrared imaging system (LI-COR) at 800 nm. 
 
Identification of additional mutations that affect ‘882 activity 
In silico docking was performed by Raju Nagarajan and Ivelin S. Georgiev. 
Protoporphyrinogen oxidase structure (PDB-id: 3I6D, chain A) from Bacillus subtilis was 
used for the structural analysis. Molecular docking simulations with ligand '882 were 
performed using the AutoDock 4.2 and AutoDock tools (108). The protein was prepared 
for docking by assigning polar hydrogens, solvation parameters, and Kollman united 
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atom charges, whereas Gasteiger charges were assigned to the ligand. Water molecules 
were removed from the input structure. The ligand was modeled as flexible around 
rotatable bonds. The grid box was centered around residues T189 and Q192 (S. aureus 
T183 and N186). Flexible docking was performed by modeling as flexible these two 
residues, as well as the nearby Y177, F190 and F193. The default grid box size was 
adjusted to allow a free rotation of the ligand, and set at 70x70x70, with a grid spacing of 
0.375 Å. Grid maps were generated using the AutoGrid program. The Lamarckian 
genetic algorithm (LGA) was used for the conformer search, with default parameters, 
including selection window (10 generations), population size (150) and maximum 
number of energy evaluations (2,500,000) (109). A total of 8,000 docked conformations 
were generated, and the 100 lowest-energy models were selected for further analysis. 
Potential mutations at residues, for which at least one ligand conformation (from the top 
100) was within 4 Å, were modeled structurally, for selection of mutations to destabilize 
the interactions between the protein and the ‘882 ligand. Structural models were 
visualized using the PyMOL software. Two types of mutations were selected for 
experimental validation: (i) larger amino acid side chains that could sterically hinder 
ligand binding but that could be accommodated within the protein binding pocket, or (ii) 
Ala substitutions at residues that were found to have substantial ligand interactions in the 
docking models. 
 
Light source and photosensitivity assays 
A light source was engineered using an array of 135 individual 410 nm LED 
lights (Tianhui Electronic Co. Ltd) mounted in a custom laser-cut acrylic frame and 
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powered with a wall transformer to produce 1.41 mW/cm2 over the entire surface of a 96-
well plate. All light killing experiments were performed on three separate days and 
averaged. Student’s t-test was performed to determine significance. 
An overnight culture of S. aureus in RPMI supplemented with 1% casamino acids 
and 0.5 mM EDDHA was subcultured 1:50 into RPMI supplemented with 1% casamino 
acids and either 50 µM ‘882, 120 mM delta aminolevulinic acid hydrochloride (Frontier 
Biosciences), or a combination of the two. The culture was grown for 2 hours. An 
overnight of S. epidermidis in RPMI supplemented with 1% casamino acids was 
subcultured 1:50 into RPMI supplemented with 1% casamino acids and either 50 µM 
‘882, 3.8 mM delta aminolevulinic acid hydrochloride (Frontier Biosciences), or a 
combination of the two. The culture was grown for 2 hours. Cells were diluted 1:10 into 
PBS. Twenty-five µL were transferred into a flat bottom 96 well plate and exposed to 
light to 0 or 2.5 J/cm2.  
An overnight culture of B. anthracis in RPMI supplemented with 1% casamino 
acids was subcultured 1:50 into RPMI supplemented with 1% casamino acids and either 
50 µM ‘882, 3.8 mM delta aminolevulinic acid hydrochloride (Frontier Biosciences), or a 
combination of the two. The culture was grown for 5 hours, diluted 1:10 into PBS. 
Twenty-five µL were transferred into a flat bottom 96 well plate and exposed to light for 
to 0 or 2.5 J/cm2. The bacteria were serially diluted, plated, and CFUs were counted after 
20 hours of growth on LB agar. 
A five-day anaerobic culture of P. acnes in BHI was removed from the anaerobic 
chamber (Coy) and subcultured 1:100 into BHI with either 50 µM ‘882, 230 µM delta 
aminolevulinic acid hydrochloride (Frontier Biosciences), or a combination of the two. 
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The culture was grown for 24 hours under anaerobic conditions. The culture was then 
removed from the anaerobic chamber and diluted 1:10 into PBS. Twenty-five µL were 
transferred into a flat bottom 96 well plate and exposed to light for to 0 or 5 J/cm2. The 
bacteria were serially diluted, plated, and CFUs were counted after 5 days of growth on 
BHI agar. Data are represented as mean ± SEM. 
 
Superficial skin infection 
All mice were maintained in compliance with Vanderbilt’s Institutional Animal 
Care and Use Committee regulations. Animals were infected as previously described 
using a tape-stripping model of infection (110). Six-to-eight week old female Balb/cJ 
mice or C57BL/6J mice were used for S. aureus and P. acnes infections, respectively. 
Briefly, stationary phase S. aureus cells grown in RPMI + 1% casamino acids + 0.5 mM 
EDDHA were washed with PBS, and approximately 2 x 108 CFU were inoculated in 5 
µL of PBS. Twenty-four hours post infection, and each day thereafter, mice were left 
untreated, treated with 20 µL of 1 mM ‘882 in 2% Tween-80 in PBS with 2.5 J/cm2 of 
410 nm light two hours after exposure to compound. The size of each wound was 
calculated each day following infection by measuring dimensions on each animal and 
compared by Student’s t-test. The presence of wound over the course of the infection was 
followed. Error and significance were determined using Prism’s (GraphPad) function 
“Survival Curve Analysis.” 
Exponential phase P. acnes were washed in PBS and 2 x 108 CFU were inoculated 
in 5 µL of PBS. Thirty minutes post infection mice were untreated, or treated with either 
50 µL 1.2 M ALA in 2% Tween-80 in PBS, 50 µL 1 mM ‘882 in 2% Tween-80 in PBS, 
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or 50 µL 1.2M ALA and 1 mM ‘882 in 2% Tween-80 in PBS. Two hours later mice were 
exposed to 2.5 J/cm2 410 nm light. Mice were harvested 22 hours post infection. Skin 
samples containing the wound were homogenized using a Bullet Blender (Next 
Advanced) according to the manufacturer’s instructions. The homogenate was serially 
diluted and plated. Data are represented as mean ± SEM. Student’s t-test was performed 
to determine significance. 
 
Chemical Synthesis 
Chemical synthesis was performed by Brendan Dutter, PhD and Gary Sulikowski, 
PhD. 
General Procedures: All non-aqueous reactions were performed in flame-dried 
flasks under an atmosphere of argon. Stainless steel syringes were used to transfer air- 
and moisture-sensitive liquids. Reaction temperatures were controlled using a 
thermocouple thermometer and analog hotplate stirrer. Reactions were conducted at room 
temperature (rt, approximately 23 °C) unless otherwise noted. Flash column 
chromatography was conducted using silica gel 230-400 mesh. Analytical thin-layer 
chromatography (TLC) was performed on E. Merck silica gel 60 F254 plates and 
visualized using UV and iodine stain.  
Materials: All solvents and chemicals were purchased from Sigma-Aldrich 
unless otherwise noted. Dichloromethane (DCM) and tetrahydrofuran (THF) were used 
as received in a bottle with a SureSeal. Triethylamine was distilled from calcium hydride 
and stored over KOH. Deuterated solvents were purchased from Cambridge Isotope 
Laboratories. Trimethylsilylacetylene was purchased from Oakwood Chemicals. S1 and 
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S3 were prepared using previously described procedures (111, 112). Biotin azide (PEG4 
carboxamide-6-azidohexanyl biotin) was prepared by the Vanderbilt Institute of 
Chemical Biology chemical synthesis core. The preparation and characterization of ‘882 
derivatives presented in Table 8, with exception of ‘882-PAL, has been previously 
described (49). 
Instrumentation: 1H NMR spectra were recorded on Bruker 400 or 600 MHz 
spectrometers and are reported relative to deuterated solvent signals. Data for 1H NMR 
spectra are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, m = multiplet, br = broad, app = apparent), 
coupling constants (Hz), and integration. 13C NMR spectra were recorded on Bruker 100 
or 150 MHz spectrometers and are reported relative to deuterated solvent signals. 19F 
NMR were recorded on a Bruker 376 MHz spectrometer. Low resolution mass 
spectrometry (LRMS) was conducted and recorded on an Agilent Technologies 6130 
Quadrupole instrument.  
Experimental Procedures: 
1-(2-hydroxy-4-((trimethylsilyl)ethynyl)phenyl)ethanone 
(S2). To a stirred solution of 4-bromo-2-hydroxyacetophenone (S1) (220 mg, 1.02 mmol) 
in tetrahydrofuran (4 mL) was added triethylamine (284 µL, 2.04 mmol), 
bis(triphenylphosphine)palladium dichloride (36.0 mg, 0.051 mmol), copper(I) iodide 
(9.7 mg, 0.051 mmol), and trimethylsilylacetylene (216 µL, 1.53 mmol).  The mixture 
was stirred overnight at room temperature under an atmosphere of argon until judged 
S2
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complete by TLC. The reaction was filtered through Celite, concentrated, and purified by 
flash chromatography to provide 208 mg (88 %) of S2 as white crystals. 1H NMR (400 
MHz, CDCl3) δ 7.64 (d, J=8.24 Hz, 1H), 7.85 (d, J=1.40 Hz, 1H), 6.96 (dd, J=8.24 Hz, 
J=1.52 Hz, 1H), 2.61 (s, 3H), 0.23 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 204.0, 162.1, 
131.2, 130.6, 122.5, 121.7, 119.5, 103.7, 98.8, 26.8, -0.1; LRMS calculated for 
C13H17O2Si+ (M+H)+ m/z: 233.1, measured 233.2. 
2-acetyl-5-((trimethylsilyl)ethynyl)phenyl 4-(3-
(trifluoromethyl)-3H-diazirin-3-yl)benzoate (S4). To a stirred solution of phenol S2 
(82.0 mg, 0.355 mmol) dissolved in dichloromethane (1 mL) was added triethylamine (54 
µL, 0.390 mmol), one crystal of 4-dimethylaminopyridine, and benzoyl chloride S32 
(97.0 mg, 0.390 mmol) dissolved in dichloromethane (0.5 mL). The reaction was stirred 
at room temperature for 1 h until judged complete by TLC analysis. The reaction was 
diluted with dichloromethane (20 mL), washed with saturated NaHCO3, brine, dried 
(MgSO4), and concentrated to provide 138 mg (86 %) of benozate S4. 1H NMR (400 
MHz, CDCl3) δ 8.21 (dt, J=8.60 Hz, J=1.80 Hz, 2H), 7.80 (d, J=8.08 Hz, 1H), 7.44 (dd, 
J=8.08 Hz, J=1.52 Hz, 1H), 7.35 – 7.31 (m, 3H), 2.51 (s, 3H), 0.25 (s, 9H); 19F NMR 
(376 MHz, CDCl3) δ -67.9. 
5-ethynyl-2-(5-(4-(3-(trifluoromethyl)-3H-
diazirin-3-yl)phenyl)-1H-pyrazol-3-yl)phenol (‘882-PAL). To a stirred solution of 
S4
8882-PAL
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ester S4 (138 mg, 0.310 mmol) dissolved in THF (1.5 mL) at 0 °C was added 0.5 M 
KHMDS in toluene (1.24 mL, 0.620 mmol). The reaction was maintained at 0 °C for 1.5 
h at which point it was judged complete by TLC. The reaction was quenched by addition 
of 1 N HCl and the resulting mixture extracted with diethyl ether, concentrated, the 
residue flash filtered through silica gel with hexane/ethyl acetate (4:1), and concentrated 
again to provide 60.1 mg of crude diketone which was carried through to the next step 
without purification or characterization. The crude diketone (60.1 mg) was dissolved in 
4.5 mL ethanol containing hydrazine hydrate (8.7 µL, 0.136 mmol). The reaction was 
maintained at room temperature until judged complete by LCMS (2 h). The reaction was 
concentrated and dissolved in methanol (1 mL) and potassium carbonate (19 mg, 0.136 
mmol) was added. The reaction was stirred for 30 min until judged complete by LCMS. 
The reaction was partitioned between water and ethyl acetate. The organic layer was 
washed with brine, dried (MgSO4), filtered and concentrated. The crude residue was 
purified by preparative scale reverse phase HPLC to provide 14.2 mg (12 % over 2 steps) 
of ‘882-PAL (Figure 11). 1H NMR (600 MHz, CD3OD) δ 7.88 (d, J=8.52 Hz, 2H), 7.66 
(d, J=8.40 Hz, 1H), 7.32 (d, J=8.22 Hz, 2H), 7.16 (s, 1H), 7.03 – 7.00 (m, 2H), 3.50 (s, 
1H); 13C NMR (150 MHz, CD3OD) δ 159.6, 133.9, 129.7, 127.3, 124.4, 123.6 (q, 
J=273.9 Hz), 120.7, 118.6, 101.9, 84.2, 78.9, 29.5 (q, J=40.4 Hz); 19F NMR (376 MHz, 
CD3OD) δ -67.0; LRMS calculated for C19H12F3N4O+ (M+H)+ m/z: 369.1, measured 
369.2 (Figure 12). 
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Figure 11. Synthesis of ‘882-PAL. 
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Figure 12. 1H NMR spectrum of ‘882-PAL in CD3OD. 
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RESULTS 
 
Selection of ‘882-resistant suicide strains 
The suicide strain was constructed as described in Chapter II (Figure 13c-d). 
Isolates of hrtAB::relE exhibiting spontaneous resistance to ‘882 were identified, and the 
stability of resistance was ensured through serial passage. Genomic DNA was isolated 
and the hssRS/hrtAB locus was sequenced. Whole genome sequencing was performed on 
isolates lacking mutations in hssRS/Phrt to identify mutations conferring resistance to 
‘882 in the hrtAB::relE strain background. This analysis revealed a T183K mutation in 
HemY, an enzyme required for heme biosynthesis. The HemY T183K mutation was 
reconstructed in WT S. aureus (hemY.T183K), and this strain exhibits normal growth 
suggesting the HemY T183K mutation prevents the response of S. aureus to ‘882 without 
restricting heme biosynthesis, as seen in a strain lacking HemY (DhemY) (Figure 13e) 
(113). In addition, the T183K mutation abolished ‘882 sensing to the same level as 
DhssRS, while heme sensing remained intact (Figure 13f). Taken together, these results 
demonstrate that the HemY T183K mutation prevents ‘882-induced activation of hrtAB 
in S. aureus. 
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Figure 13. ‘882 exposure increases CPIII production in S. aureus.  
(a) The terminal enzymes in the Gram-positive heme biosynthesis pathway (red) are distinct from other 
organisms. (b) ‘882 is a small molecule that increases heme biosynthesis in S. aureus (47). (c) To create a 
Phrt suicide strain, the hrtAB genes were replaced with two copies of the E. coli gene encoding the RNA 
interferase toxin RelE. (d) Upon heme or ‘882 stimulation, toxicity is induced in hrtAB::relE. (e) Strain 
hemY.T183K exhibits a normal growth phenotype on TSA suggesting the HemY T183K does not restrict 
HemY function. (f) Strain hemY.T183K is unresponsive to ‘882, but retains the ability to respond to heme 
as measured by Phrt activation. * denotes p<0.001 compared to vehicle treated for each strain. (g) HPLC 
analysis of WT, hemY.T183K, and DhemY ± ‘882. ‘882 increases CPIII production in WT cells but not in 
hemY.T183K. (Inset) ‘882-induced CPIII accumulation induces fluorescence in treated cells.  
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‘882 induces CPIII accumulation 
To determine the impact of ‘882 on the heme biosynthesis pathway, intermediates 
of heme biosynthesis were quantified following ‘882 exposure. Porphobilinogen (PBG), 
an early heme biosynthetic precursor, is unaffected by ‘882 (Figure 13a, Figure 14). In 
contrast CPIII, the product of HemY, is greatly increased following ‘882 treatment 
(Figure 13a, g). Notably, CPIII accumulation is not observed in hemY.T183K or DhemY 
upon ‘882 treatment (Figure 13g). CPIII is the only fluorescent molecule in the heme 
biosynthesis pathway and ‘882 exposure triggers dramatic fluorescence in S. aureus 
(Figure 13g, inset). The HPLC fraction corresponding to the elution time of the CPIII 
standard was analyzed by LC-MS/MS and confirmed to be CPIII (Figure 15). These 
results demonstrate that ‘882 exposure leads to accumulation of CPIII in S. aureus and 
implicate HemY as a candidate target of the molecule. 
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Figure 14. ‘882 does not affect early heme biosynthesis. 
 Porphobilinogen (PBG) was quantified to determine ‘882-induced effects on early heme biosynthesis 
intermediates. No effect on PBG was seen.  
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Figure 15. ‘882 induces accumulation of CPIII.  
HPLC fractions containing either the CPIII standard peak or the corresponding fraction from ‘882 treated 
WT cells were analyzed by LC-MS/MS. MS/MS fragmentation of the peak at m/z 654.340, the mass of 
CPIII, is shown. The MS/MS fragmentation of this peak in both samples is nearly identical and consistent 
with expected major fragments, positively identifying the peak within these fractions as CPIII. 
 
 
  
 72 
‘882 activates HemY from Gram-positive bacteria in vitro 
To determine whether ‘882 directly activates S. aureus HemY, recombinant S. 
aureus WT HemY and HemY T183K were purified. Importantly, these two enzymes 
display similar KM and Vmax values, demonstrating the T183K mutation does not affect 
baseline HemY activity (Figure 16g, Figure 17a). Upon treatment with ‘882, WT HemY 
displayed 205% activity with an AC150 of 92 nM, whereas the T183K mutant did not 
respond to ‘882 at concentrations up to 10 µM (Figure 16a, g). These data establish ‘882 
as a small molecule activator of HemY. 
To determine if ‘882 retains activity against HemY from other Gram-positive 
organisms, recombinant Bacillus subtilis and P. acnes HemY were purified (32). KM and 
Vmax values were determined to characterize baseline activity of the enzymes, and each 
was tested for ‘882-induced activation (Figure 16b and g, Figure 17b). ‘882 activates 
HemY from B. subtilis and P. acnes with AC150 values of 42 and 16 nM, respectively 
(Figure 16b, g). Importantly, human HemY, a protoporphyrinogen oxidase as opposed to 
a coproporphyrinogen oxidase, did not respond to ‘882 treatment (Figure 16c, Figure 
17c). These results establish ‘882 as a small molecule activator of HemY from Gram-
positive bacteria.  
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Figure 16. ‘882 activates HemY from Gram-positive bacteria and identification of a region important 
for regulation of HemY.  
(a-b, f) HemY activity was assayed with increasing ‘882 concentrations and 5 µM CPGIII. (c) HemY 
activity was assayed with increasing ‘882 concentrations and 5 µM PPGIX. (d) The residue of B. subtilis 
HemY homologous to S. aureus T183 (blue) is located in a region distinct from the active site (Y366, 
yellow) (114, 115). B. subtilis HemY shares 46% identity with S. aureus HemY. A residue homologous to 
S. aureus N186 (red) faces a cleft leading into the active site. (e) Magnified view of residues homologous 
to S. aureus T183 and N186 residues (carbon in light blue, nitrogen in dark blue, and oxygen in red). (g) 
KM, Vmax, AC150, and activation (%) for each enzyme were determined. 
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Figure 17. Characterization of HemY activity from Gram-positive bacteria and H. sapiens.  
(a-d) Activities of recombinant HemY from S. aureus (WT, T183K, N186Y, N186F), B. subtilis, P. acnes, 
and H. sapiens with varying concentrations of coproporphyrinogen III (CPGIII) for Gram-positive HemY 
and protoporphyrinogen IX (PPGIX) for H. sapiens HemY to determine KM and Vmax. 
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Structure activity relationship (SAR) studies of ‘882 
Recently a series of structural analogs of ‘882 were prepared and screened in a 
phenotypic HssRS activation assay using a XylE reporter gene to monitor transcription of 
hrtAB as a response to heme accumulation (Table 8) (49). These analogs were assayed in 
the HemY activation assay using WT and T183K mutant enzymes (Table 8). Three 
analogs (74-1B, VU0420372, 74-1A) proved superior or comparable to ‘882 as HemY 
activators in vitro. Notably, none of these more potent activators exhibit increased ability 
to trigger hrtAB expression in S. aureus over that of ‘882, suggesting that these 
compounds do not efficiently enter the bacterial cell. In addition, these ‘882 derivatives 
are also inactive against the T183K mutant suggesting all four diarylpyrazoles share a 
common binding site. The remaining eight diarylpryazoles were equally inactive when 
assayed against HemY or the T183K mutant. Collectively these SAR studies support 
activation of HemY by a common allosteric binding site. 
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Table 8. Structural analogs of ‘882 activate HemY. 
Structure Compound 
In vivo activity:  
% activity of            
'882 at 50 μM 
(SEM) 
In vitro activity:  
% activity of WT  
HemY at 1 μM  
 (SEM) 
In vitro activity:  
% activity of T183K 
HemY at 1 μM  
 (SEM) 
 
VU0038882 100 (9) # 192 (21) 69.3 (8.8) 
 
 
74-1B 0.335 (0.276) # 300 (42) 72.3 (11.5) 
 
 
VU0420372 1.67 (0.55) # 230 (40) 72.1 (7.5) 
 
 
74-1A 0.206 (0.113) # 153 (15) 35.7 (4.7) 
 
 
VU0420382 0.812 (0.297) # 128 (12) 78.3 (7.9) 
 
 
VU0125897 28.2 (0.8) # 112 (16) 110 (19) 
 
 
VU0476720 0.392 (0.146) # 111 (13) 95.6 (9.7) 
 
 
VU0476725 0.299 (0.188) # 109 (17) 137 (12) 
 
 
VU0366053 0.715 (0.093) # 89.6 (11.4) 106 (12) 
 
 
VU0404345 1.19 (0.31) # 81.9 (24.4) 75.8 (10.0) 
 
 
VU0476722 0.286 (0.136) # 79.4 (9.0) 95.2 (15.2) 
 
 
82A 0.245 (0.036) # 77.8 (14.9) 72.1 (9.5) 
 
‘882-PAL 59.0 (2.5) * 165 (26) 125 (35) 
# Previously published data (49).  
* ‘882-PAL was tested at 10 µM in XylE assay and compared to 10 µM ‘882. 
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‘882-photoaffinity probe interacts with HemY in S. aureus lysates 
Guided by the SAR data, an ‘882 photoaffinity probe (‘882-PAL) incorporating 
an alkyne moiety for click chemistry was prepared and confirmed to be active in S. 
aureus (Table 8). To determine if ‘882 directly interacts with HemY, lysates from WT 
and DhemY were prepared and treated with ‘882-PAL followed by photocrosslinking and 
then Cu catalyzed ligation of an azido-biotin reporter to the photolabelled proteins. A 
band corresponding to the molecular weight of HemY (52 kDa) was identified by 
detection of the biotin tag ligated to ‘882-PAL (Figure 18). This band is not present in 
lysate from DhemY, and is dependent upon the addition of the biotin tag (Figure 18). 
These results establish that ‘882 specifically interacts with HemY from S. aureus lysates. 
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Figure 18. ‘882-PAL is active and identifies HemY in S. aureus lysate.  
(a) ‘882-PAL was incubated with lysate from S. aureus and photocrosslinked. Click reaction was 
performed to add the biotin tag. Detection of biotinylated proteins was performed using a streptavidin 
conjugated fluorophore. A band at the approximate molecular weight (arrow, 52 kDa) of HemY was 
identified in WT lysate and not in DhemY lysate or in the absence of the biotin tag. (b) Ponceau S stain to 
verify protein loading was consistent across samples. 
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Structural analysis of the ‘882-HemY interaction  
To gain insight into the potential binding site of ‘882 within HemY, the 
previously solved crystal structure of B. subtilis HemY was interrogated (Figure 16d) 
(115). Based on the location of S. aureus T183 within HemY, a nearby amino acid, N186, 
was implicated as potentially important due to its proximity on a short helix facing a cleft 
leading into the active site (Figure 16d, e). The N186 residue was altered to tyrosine or 
phenylalanine and the activity of the resulting enzyme variant was examined in the 
presence or absence of ‘882 (Figure 16f and g, Figure 17d). HemY N186Y and HemY 
N186F exhibit increased baseline activity relative to WT HemY, suggesting this region is 
important for positive enzyme regulation (Figure 16g, Figure 17d). Consistent with this, 
both mutations abolishes the ability of HemY to respond to ‘882 treatment (Figure 16f, 
g). Importantly, the helix containing these residues is in a distinct region from the active 
site of the molecule (Figure 16d). Taken together, these data support a model whereby 
‘882 binds to the region of HemY containing residues 183 to 186 and acts as an allosteric 
modulator of enzyme activity. Mutations in this portion of the enzyme may mimic ‘882-
induced changes in tertiary structure leading to enzyme activation. 
 
In silico docking identifies a functional domain important for ‘882 activation 
To further our understanding of the functional domain required for ‘882 activity, 
the ‘882-HemY interaction was modeled by in silico docking to identify additional 
residues that may be required for ‘882-induced activity of HemY. Based upon this 
analysis, six more residues within HemY were selected for mutational analysis to 
interrogate their importance for ‘882-dependent activation (Figure 19a). Mutations were 
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made in S. aureus hemY creating the enzyme variants V146M, M167F, Y171A, F184A, 
F187W, and D450Y. Upon induction, V146M, Y171A, F184A, and D450Y led to 
unstable enzymes that could not be purified (Figure 10). HemY M167F and F187W 
expressed equivalently to WT (Figure 10), were purified, and interrogated for ‘882-
induced activation. Both mutations inhibited the activation of HemY by ‘882 (Figure 
19b). Taken together, these data begin to define a pocket within HemY that appears to be 
required for ‘882-dependent activation of the enzyme (Figure 19c).  
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Figure 19. Identification of additional mutations that affect ‘882 activity.  
(a) Distribution of ligand-residue distances for the subset of protein residue positions for which at least one 
of the top 100 ligand conformations was within 4 Å, shown as boxplots (box represents 25th and 75th 
percentile, and the horizontal line inside the box represents the median; vertical bars span between the min 
and max values). The two residues used to guide the docking are shown in cyan, whereas the two additional 
residues that were identified by the modeling approach and confirmed to have the desired disruption of 
‘882 activity are shown in red. Structural analysis was performed on the B. subtilis crystal structure, 
homologous residue numbers to the S. aureus sequence are displayed (115). (b) HemY activity was assayed 
with ‘882 and 5 µM CPGIII. (c) Structural model highlighting the same four residues as in the boxplot in 
the B. subtilis structure (115). 
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HemY activation induces photosensitization of Gram-positive bacteria 
Photodynamic therapy (PDT) is frequently used to treat bacterial skin infections 
and involves the use of a photosensitizer and a light source to destroy cells through the 
production of reactive oxygen species (16). Porphyrin intermediates of the heme 
biosynthesis pathway are the most common photosensitizers used in clinics. The 
production of porphyrin intermediates is often upregulated through the addition of 
aminolevulinic acid (ALA), the first committed precursor in the heme biosynthetic 
pathway (Figure 13a). A major limitation of ALA-PDT for the treatment of infectious 
diseases is the lack of specificity of this therapy, which induces photosensitivity in both 
bacterial and human cells. Due to the specificity of ‘882 for HemY from Gram-positive 
bacteria, this molecule should selectively sensitize bacteria to light while avoiding host 
toxicity. To test this hypothesis, S. aureus grown in the presence of ALA or ‘882 were 
exposed to 410 nm light, the excitation maximum for CPIII. Both ALA and ‘882 
treatment led to significant growth inhibition of S. aureus following exposure to 2.5 
J/cm2 of light (Figure 20a). A synergistic effect was seen when ‘882 and ALA were 
added together, likely due to ALA increasing precursor availability for HemY. Notably, 
ALA and ‘882 combined decreased S. aureus viability by four logs compared to 
untreated cells (Figure 20a). The toxicity of ‘882-PDT is conserved across some of the 
most important causes of human skin infections, including S. epidermidis, B. anthracis, 
and P. acnes (Figure 20b-d). These results establish the utility of ‘882-PDT as a potential 
therapeutic for the treatment of skin infections, most often caused by Gram-positive 
bacteria. 
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Figure 20. ‘882 induces photosensitivity in Gram-positive pathogens.  
(a-d) S. aureus, S. epidermidis, B. anthracis, and P. acnes were exposed to ALA, ‘882, or ALA+’882 in the 
presence or absence light. * denotes p<0.05 compared to untreated. (e) Mice infected with S. aureus were 
treated daily with ‘882 ± 2.5 J/cm2 light. Wound size was imaged three days post infection. (f) Wound size 
was quantified two days post infection. n=22, * denotes p<0.05. (g) Mice with wounds were quantified 
over the course of infection. n=15, * denotes p<0.05. (h) Mice infected with P. acnes were treated and 
bacteria quantified in the wound 22 hours post infection. * denotes p<0.01 compared to untreated. 
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‘882-PDT increases wound healing and decreases bacterial burdens in vivo 
To determine the in vivo efficacy of ‘882-PDT, a murine model of cutaneous S. 
aureus infection was employed, which leads to considerable skin ulceration (Figure 20e) 
(110). Mice infected with S. aureus and treated with ‘882-PDT exhibited a 37% reduction 
in ulcer size following infection as compared to untreated animals (Figure 20e, f). 
Furthermore, ‘882-PDT increases healing rates, with 54% of mice having no visible 
lesion within four days (Figure 20g). To evaluate the broad utility of ‘882-PDT as a 
therapy for common skin infections, the efficacy of ‘882-PDT in a murine model of P. 
acnes infection was determined. ‘882-PDT led to a significant decrease in bacterial 
burden, highlighting the utility of ‘882 as a novel compound for the treatment of acne 
(Figure 20h). Taken together, these findings establish photodynamic therapy coupled 
with small molecule activation of HemY as an effective therapeutic strategy to 
specifically target Gram-positive pathogens.  
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DISCUSSION 
 
These results define the small molecule ‘882 as an activator of Gram-positive 
HemY. Residues required for ‘882-induced activation have been identified, thereby 
revealing a functional domain involved in the activation of HemY. In addition, treatment 
with ‘882 leads to photosensitization of Gram-positive bacteria, reducing tissue 
ulceration and bacterial burdens in vivo. Taken together, these results establish ‘882 as an 
activator of Gram-positive HemY and provide proof-of-principle for small molecule 
activation of HemY as a potential therapeutic strategy for the treatment of bacterial 
infections. 
Synthetic small molecule activators are rare, with only a handful identified to date 
(116). Identifying the targets of small molecules is a major obstacle in biomedical 
research (50-52). Phenotypic high-throughput screens utilizing small molecule libraries 
often result in the identification of numerous molecules with unknown targets. Several 
approaches have been successful in identifying intracellular targets of small molecules 
(53-59). Here we report a genetic selection strategy based on the creation of a suicide-
strain that enables the identification of spontaneous resistant mutants to an activating 
compound that is typically non-toxic. This strategy can be adapted to a variety of systems 
where a small molecule activates a specific gene expression program, and may enable the 
identification of targets for numerous small molecule activators. 
The mechanisms by which heme biosynthesis is regulated in Gram-positive 
bacteria are largely unknown (21). The identification of ‘882 as an activator of HemY 
establishes this molecule as a valuable tool for interrogating the heme biosynthetic 
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pathway in Gram-positive bacteria to further understand the synthesis of this essential 
cofactor. Interestingly, it has previously been demonstrated that HemY activity is 
modulated in vitro to a similar extent by addition of HemQ, the terminal enzyme in the 
Gram-positive heme biosynthesis pathway(34). This suggests that the interaction of 
HemY with ‘882 may not be a random occurrence, but may represent an inappropriate 
hijacking of a normal in vivo regulatory mechanism. ‘882-dependent activation of heme 
biosynthesis represents a valuable tool for studying the regulation of heme biosynthesis in 
Gram-positive bacteria. 
Notably, enzyme activators have numerous properties that make them ideal 
therapeutics (116). Whereas inhibitors often require the ability to inhibit the enzyme by 
90%, activators can induce phenotypes with small increases in enzyme activity, 
indicating that derivatives of ‘882 with slight increases in activity could lead to dramatic 
increases in CPIII accumulation and therefore antibacterial properties (116). Specifically, 
this has been seen with small molecule activators of glucokinase, where a 1.5-fold 
increase in enzymatic activity has shown significant effects in vivo. These molecules are 
now used as therapeutics for diabetes (117).  
In addition, inhibitors often bind active sites of enzymes, which are typically well 
conserved across homologous enzymes. In contrast, activators often bind allosteric sites, 
which are less well conserved across enzymes thus increasing specificity and limiting off-
target effects (116-118). Structural analysis of the ‘882-HemY interaction has identified a 
functional domain of HemY that suggests an allosteric mechanism of action for ‘882-
induced activation (Figure 16, Figure 19). In addition, we have identified specific 
residues that when altered increase activity, further supporting that this portion of the 
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enzyme is important in positive regulation (Figure 17). Therefore, ‘882 and its derivatives 
have value as both probes of heme biosynthesis as well as small molecule 
photosensitizers for the treatment of bacterial infections.  
The use of PDT has begun to expand beyond SSTIs. Gastrointestinal endoscopes 
have been developed that emit wavelengths that activate porphyrins in patients to detect 
cancer, and similar strategies have been interrogated for their ability to treat 
gastrointestinal infections (68, 69). Osteomyelitis and contamination of orthopedic 
devices are some of the most common invasive bacterial infections, and PDT strategies to 
combat these infections are being developed (66, 70-75). Finally, PDT-based strategies 
are in development for a variety of other diseases including parasitic, dental, and sinus 
infections (67, 76). As the utility of PDT-based therapies expands, so too will the 
potential clinical utility of small molecule activators of HemY. 
The ability of ‘882 to specifically photosensitize Gram-positive bacteria 
circumvents the non-specific nature of ALA-PDT, which has limited the value of ALA-
PDT for the treatment of infectious diseases (16, 64, 65). Furthermore, this provides 
proof-of-concept that activation of bacterial porphyrin production through specific 
activation of HemY is a viable therapeutic strategy that could be adapted to Gram-
negative bacteria and other infectious diseases (16, 63, 67). Therefore, the development 
of ‘882-PDT has the potential to significantly expand the value of light-based therapies 
for the treatment of the most common causes of skin infections. 
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CHAPTER IV. BACTERIAL NITRIC OXIDE SYNTHASE IS REQUIRED FOR THE 
STAPHYLOCOCCUS AUREUS RESPONSE TO HEME STRESS 
 
INTRODUCTION 
 
Staphylococcus aureus is a Gram-positive pathogen that causes significant 
morbidity and mortality worldwide (5-8). Diseases caused by S. aureus range from 
superficial skin infections to invasive disease with considerable mortality. In this regard, 
S. aureus is a leading pathogen associated with life-threatening blood stream infections 
(3). Furthermore, recent isolates exhibit significantly decreased susceptibility to the 
current antibacterial armamentarium (119). This has led to efforts focused on an 
increased understanding of the pathogenesis of this organism in order to identify novel 
therapeutic targets for the treatment of staphylococcal infection.  
In order to colonize the vertebrate host, S. aureus requires numerous nutrients, 
such as heme (120). The heme requirement can be satisfied through two distinct 
mechanisms: importing exogenous heme through dedicated machinery or synthesizing 
endogenous heme de novo from metabolic precursors. Both heme acquisition and heme 
synthesis are required for full virulence of S. aureus (26, 27). Once acquired, heme is 
used for various processes in the cell. Intact heme is utilized as a cofactor for enzymes 
including cytochromes in the electron transport chain, catalase for the detoxification of 
reactive oxygen species, and bacterial nitric oxide synthase (bNOS). Heme can also be 
employed as a nutrient iron source for bacteria, through degradation by heme oxygenases 
to release free iron (31).  
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Although required to colonize the host, excess heme is toxic to bacteria. Thus, the 
ability to sense and detoxify heme is critical to many pathogens (46). Specifically, 
multiple Gram-positive pathogens sense heme through the heme sensor system (HssRS) 
two-component system (44, 46). Upon activation, HssRS induces the expression of the 
heme-regulated transporter (hrtAB), which encodes an efflux pump that alleviates heme 
toxicity (44, 45). The coordinated efforts of HssRS and HrtAB enable these pathogens to 
grow in the presence of high heme concentrations. Deletion of components of this 
pathway affect the virulence of S. aureus (46). Understanding the mechanism of HssRS 
activation will provide insight into the ability of pathogens to sense this required cofactor 
and survive within the hostile environment of the vertebrate host.  
Recent studies have found that bacterial nitric oxide (NO) synthesis is important 
for bacterial survival in the host, and suggest multiple roles for NO during bacterial 
infections (121). Bacterial pathogens encode genes similar to mammalian nitric oxide 
synthases, which led to the characterization of the bacterial nitric oxide synthase (bNOS) 
hemoprotein (30). The critical role of bNOS has been established in a number of 
organisms including S. aureus and Bacillus anthracis, where bNOS has been shown to 
protect against various antibiotics and oxidative stress (121-124). Considering its 
contribution to virulence of these organisms, bNOS has been identified as a potential 
drug target for the treatment of infections (125). 
We have previously reported a high-throughput screen (HTS) for activators of 
staphylococcal HssRS (47). This screen resulted in the identification of multiple chemical 
probes that activate HssRS (47, 49). One such probe, VU0038882 (‘882), activates 
staphylococcal heme biosynthesis, providing a powerful tool for understanding heme 
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biosynthesis in the context of heme sensing and infection (47). In this manuscript, we 
describe the mechanism of HssRS activation by VU0043981 (‘3981), a second compound 
identified in the same HTS. Importantly, in contrast to ’882, ‘3981 activates HssRS 
independently of heme accumulation, providing a unique probe to interrogate the heme 
sensing system. In this regard, a transposon screen utilizing a ‘3981-derived probe 
uncovered bNOS as crucial to the heme stress response, providing evidence that nitric 
oxide and heme sensing are linked in staphylococci. 
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METHODS 
 
Bacterial strains, growth conditions, and plasmids  
Cloning was performed in Escherichia coli DH5a (Invitrogen™). S. aureus 
strains were grown in tryptic soy broth (TSB) or agar (TSA), and E. coli in lysogeny 
broth (LB) or agar (LBA). Strains and plasmids used in this study are described in Table 
9 and Table 10, respectively. 
S. aureus strain allele nos::ermC was described previously and was transduced 
into Newman using the f85 bacteriophage (creating Dnos) or strain DhrtB (creating 
DhrtB/Dnos) (29, 103). 
A complementation construct for nos was created by PCR-amplifying nos using 
Newman genomic DNA as a template, and cloning into pOS1.plgt. 
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Table 9. Bacterial strains used in Chapter IV. 
Bacterial Strain Description Reference  
Wild-type Staphylococcus aureus strain Newman (94) 
USA300 JE2 Staphylococcus aureus strain USA300 JE2 (126) 
RN4220 S. aureus cloning intermediate (96) 
DhssRS In-frame deletion of hssRS in Newman background (93) 
DhssS Transposon integration into hssS in Newman, PhiNE 01562 (SAV2362) (46) 
DhemB Transposon integration disrupting hemB, hemB::ermC, in Newman (47) 
DmenB In-frame deletion of menB in Newman (127) 
Dnos Transposon integration disrupting bNOS, nos::ermC in Newman This study 
DhrtB In-frame deletion of hrtB in Newman background (95) 
DhrtB/Dnos Transposon integration disrupting bNOS, nos::ermC in DhrtB This study 
 
 
 
 
Table 10. Plasmids used in Chapter IV. 
Plasmids  Reference  
pOS1  (128) 
pOS1.Plgt  (129) 
phrt.xylE  (46) 
plgt.xylE  (44) 
plgt.nos  This study 
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Promoter activity assay 
Promoter activity assay was performed as previously described (44). Briefly, 
phrtAB.xylE was electroporated into the strain Dnos. The other strains used have been 
previously described (47). Overnight cultures were diluted 1:100 into TSB supplemented 
with 10 µg/mL chloramphenicol and grown for 24 hours and assayed as previously 
described (46). The experiment was performed in triplicate on three separate days (n=9). 
Data are presented as mean +/- SEM. Student’s t-test was performed to determine 
significance. 
 
IC50 determination 
To determine toxicity of the compounds, S. aureus overnight cultures were 
diluted 1:100 into a 96-well plate containing 200 µL of TSB with or without 
supplementation of compound. Cultures were grown at 37°C for 7 hours (stationary 
phase of untreated bacteria) and the OD600 was determined. Data were transformed to 
percent growth of untreated bacteria, concentrations of compound were log transformed, 
and fitted using GraphPad (Prism).  
 
Heme quantification 
Quantification of intracellular heme was performed as previously described (47). 
The experiment was performed in triplicate on three separate days (n=9). Data are 
presented as mean +/- SEM. Student’s t-test was performed to determine significance. 
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Heme adaptation 
Heme adaptation assays were performed similar to previously described (46, 47). 
The assay was performed in 96-well plates with pretreatments with vehicle (DMSO), 
heme, or a ‘3981 derived compound. Briefly, colonies were selected into 150 µL TSB in 
a 96-well plate and grown for 6 hours with shaking at 37°C. Cultures were subcultured 
1:150 into the condition being tested and grown overnight. In the morning, cultures were 
subcultured again 1:150 into the heme concentration being interrogated or vehicle control 
and grown 6 hours. OD600 were determined and compared. The experiment was 
performed in triplicate on three separate days (n=9). Data are presented as mean +/- 
SEM. Student’s t-test was performed to determine significance. 
 
Transposon mutant screen 
The staphylococcal Nebraska Transposon Mutant Library was screened using the 
protocol described above (126). Cultures were pretreated with ‘7501 overnight, and 
subcultured into 50 µM heme. Hits were identified as those that were greater than two 
standard deviations below the mean growth of the plate being tested. 
 
Chemical Synthesis 
Chemical synthesis was performed by Brendan Dutter, PhD and Gary Sulikowski, 
PhD. 
General: Room temperature was approximately 23°C. Analytical thin-layer 
chromatography (TLC) was performed on E. Merck silica gel 60 F254 plates and 
visualized using UV light. All solvents and chemicals were purchased from Sigma-
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Aldrich except 3-methoxybenzylamine (Combi-Blocks). Deuterated acetone was 
purchased from Cambridge Isotope Laboratories. 1H NMR spectra were recorded on a 
Bruker 400 MHz spectrometer and are reported relative to deuterated solvent signals. 
Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm), multiplicity (s 
= singlet, d = doublet, t = triplet, dd = doublet of doublets, m = multiplet, br = broad, app 
= apparent), coupling constants (Hz), and integration. 13C NMR spectra were recorded on 
a Bruker 100 MHz spectrometer and are reported relative to deuterated solvent signals. 
Low resolution mass spectrometry (LRMS) was conducted and recorded on an Agilent 
Technologies 6130 Quadrupole instrument. 
Synthesis of Thioureas: Syntheses of ‘3981 and ‘7501 were adapted from a 
previously described procedure (130). To a stirred solution of 4-phenoxyaniline (1.0 eq) 
in dichloromethane (0.20 M) was added an equal volume of saturated sodium 
bicarbonate. The resulting biphasic mixture was cooled to 0 °C and stirred vigorously. 
Thiophosgene (1.0 eq) dissolved in a minimal amount of dichloromethane was added 
dropwise to the mixture. Once addition was complete, the mixture was stirred vigorously 
for 30 min at 0 °C. 4-fluorobenzylamine (for ‘3981) or 3-methoxybenzylamine (for 
‘7501) (1.05 eq) was added to the reaction neat and the mixture was allowed to warm to 
room temperature with vigorous stirring. When the reaction was judged complete (TLC 
or LCMS), it was diluted with dichloromethane, the aqueous layer removed, the organic 
layer washed with 1 N HCl (1x), brine (1x), dried (MgSO4), filtered, and the solvent 
removed in vacuo. The residue was purified by recrystallization from isopropanol. Yields 
were in the range of 50 – 60 % and compound purity was determined by 1H NMR and 
LC-MS.  
 97 
 
1-(4-fluorobenzyl)-3-(4-
phenoxyphenyl)thiourea (‘3981). Light yellow crystals; 1H NMR (400 MHz, acetone-
d6) δ 8.87 (br s, 1H), 7.57 (br s, 1H), 7.47 – 7.34 (m, 6H), 7.14 (t, J=7.40 Hz, 1H), 7.10 – 
7.04 (app t, 2H), 7.02 – 6.96 (m, 4H), 4.87 (d, J=5.16 Hz, 2H); 13C NMR (100 MHz, 
acetone-d6) δ 183.1, 164.0, 161.6, 158.1, 155.8, 136.3, 134.7, 130.8, 130.45, 130.37, 
127.5, 124.3, 120.1, 119.6, 115.8, 115.6, 48.0; LRMS calculated for C20H17FN2OS 
(M+H)+ m/z: 353.1, measured 353.1. 
 
1-(3-methoxybenzyl)-3-(4-phenoxyphenyl)thiourea (‘7501). Yellow crystals; 
1H NMR (400 MHz, acetone-d6) δ 8.90 (br s, 1H), 7.50 (br s, 1H), 7.46 – 7.35 (m, 4H), 
7.22 (t, J=7.86 Hz, 1H), 7.13 (t, J=7.38 Hz, 1H), 7.03 – 6.92 (m, 6H), 6.81 (dd, J=8.16 
Hz, J=1.68 Hz, 1H), 4.86 (d, J=5.68 Hz, 2H), 3.77 (s, 3H); 13C NMR (100 MHz, acetone-
d6) δ 183.0, 160.7, 158.1, 155.7, 141.6, 134.7, 130.8, 130.2, 127.5, 124.3, 120.5, 120.0, 
119.5, 114.0, 113.2, 55.4, 48.8; LRMS calculated for C21H20N2O2S (M+H)+ m/z: 365.1, 
measured 365.1.  
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RESULTS AND DISCUSSION 
 
‘3981 activates HssRS and is toxic to S. aureus 
A high-throughput screen (HTS) was performed to identify small molecule 
activators of S. aureus HssRS (47). Compound VU0043981 (‘3981) was identified in this 
HTS as an activator of S. aureus HssRS (Figure 21A, inset). ‘3981 activates HssRS in a 
dose dependent manner, and this activation is dependent upon the two-component system 
(Figure 21A). These results demonstrate that ‘3981 is an activator of HssRS leading to 
activation of hrtAB expression in S. aureus. 
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Figure 21. ‘3981 activates HssRS and is toxic to S. aureus.  
(A) Compound ‘3981 was identified in a HTS for activators of HssRS. S. aureus WT and DhssRS harboring 
phrt.xylE were treated with increasing concentrations of ‘3981. ‘3981 activates HssRS in a dose-dependent 
manner requiring the HssRS two-component system. Inset, structure of ‘3981. * denotes p < 0.05, ** 
denotes p < 0.0001. # denotes data are below the limit of detection. (B) WT, DhemB and DmenB were 
treated with increasing concentrations of ‘3981.  
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‘3981 inhibits growth of S. aureus.  
 Previously identified small molecule activators of HssRS exhibit toxicity 
to fermenting S. aureus, although the mechanism of toxicity is yet to be determined (47, 
49). In order to probe the toxicity of ‘3981 to S. aureus, WT and two respiration deficient 
strains, DhemB and DmenB, were grown in the presence of increasing concentrations of 
‘3981. DhemB and DmenB strains are deficient in production of heme and menaquinone, 
respectively, both of which are required for bacterial respiration (113). Therefore these 
strains must generate energy through fermentation. Compound ‘3981 is toxic to both WT 
and fermenting S. aureus strains (Figure 21B). Taken together, these data suggest that 
‘3981 activates HssRS and is toxic to fermenting and respiring S. aureus. 
 
‘3981 activates HssRS independent of heme accumulation  
Heme is the only identified activator of HssRS (44, 46, 47, 93). To determine if 
‘3981 activates HssRS through increasing endogenous heme biosynthesis, heme 
accumulation was quantified upon exposure to increasing concentrations of ‘3981 in the 
absence of exogenous heme. Heme accumulation was not observed in ‘3981-treated cells, 
suggesting that ‘3981 does not trigger HssRS through activation of heme biosynthesis. 
This is in contrast to ‘882, a previously identified activator of HssRS that induces heme 
biosynthesis (Figure 22) (47). Therefore, ‘3981 represents a small molecule that activates 
HssRS independently of heme accumulation, providing a unique tool to interrogate the 
heme sensing system in S. aureus. 
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Figure 22. ‘3981 does not increase endogenous heme biosynthesis.  
S. aureus was grown in the presence of ‘882 and ‘3981 and the absence of any exogenous heme source. 
‘882 activates heme biosynthesis leading to heme accumulation (47). ‘3981 does not activate heme 
biosynthesis, suggesting ‘3981 activates HssRS through a mechanism distinct from increased heme 
production. Significance was determined in comparison with vehicle treatment. * denotes p < 0.05, ** 
denotes p < 0.0001. 
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‘3981 activity requires aerobic respiration 
Although ‘3981 does not increase heme biosynthesis, heme could be required for 
‘3981-mediated activation of HssRS. Heme is utilized for numerous processes within the 
cell, including as a required cofactor for cytochromes and bacterial nitric oxide synthase 
(26, 30, 113, 123). To test the requirement for heme biosynthesis in ‘3981-dependent 
HssRS activation, the activity of ‘3981 was measured in a heme biosynthesis mutant 
(DhemB). Upon treatment of DhemB with ‘3981, activation of HssRS was not detected 
(Figure 23A). As heme is required for respiration, the requirement for aerobic respiration 
to the activity of ‘3981 was interrogated. Respiration can be disrupted through either 
inactivation of heme biosynthesis, or by growing bacteria in an anaerobic environment in 
the absence of a terminal electron acceptor. S. aureus was treated with either ‘882 or 
‘3981 during anaerobic growth. Whereas ‘882 activates HssRS in respiration defective 
strains, ‘3981 does not (Figure 23B). In order to control for growth differences between 
strains, a plasmid constitutively expressing xylE was included (plgt.xylE). Taken together 
these data suggest that ‘3981 does not activate heme biosynthesis, but its mechanism of 
action requires aerobic respiration.  
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Figure 23. ‘3981 activity is dependent on aerobic respiration.  
(A) To determine the requirement of heme synthesis for HssRS activation, S. aureus WT and DhemB 
harboring phrt.xylE were treated with increasing concentrations of ‘3981. Activation of HssRS was not 
seen in the DhemB strain. Significance was determined in comparison with vehicle treatment of phrt.xylE. 
(B) As heme is required for many cellular processes, including respiration, the ability of ‘3981 to activate 
HssRS in an anaerobic environment was tested. WT harboring phrt.xylE were treated with heme, ‘882, or 
‘3981. ‘3981 activity is dependent upon intact respiration. * denotes p < 0.05, ** denotes p < 0.0001. # 
denotes the data are below the limit of detection. 
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Structure activity relationship studies identify ‘3981 derivatives with increased 
activity 
The general toxicity of ‘3981 towards S. aureus hindered its use as a probe of 
heme sensing. Using this structure as a starting point, a library of derivatives was 
generated to determine structure-activity relationships (SAR, Table 11) and to identify 
compounds exhibiting increased HssRS activation (Figure 24A, Figure 25, Figure 26). 
The 4-biaryl ether system was determined to be required for HssRS activation as 
replacement with smaller biaryl, aryl or aliphatic groups resulted in loss of activity. The 
benzylic carbon is also required for activity as replacement the 4-fluorobenzyl with a 4-
fluorophenyl group resulted in an inactive compound. Several derivatives were 
synthesized with various substituents on the benzylamine moiety. Removal of the 
electron withdrawing 4-fluorine and substitution with an electron rich methyl ether at the 
3-position resulted in a compound, VU0047501 (‘7501), with 4x the activity of the parent 
molecule (Figure 24A, B). In addition to increased HssRS activation, ‘7501 was 
considerably less toxic than ‘3981 (Figure 24C). Furthermore, ‘7501 retained identical 
phenotypes to ‘3981 in regards to an inability to induce heme accumulation and a 
requirement for aerobic respiration (Figure 27). Due to the increased activity and lack of 
toxicity, ‘7501 was utilized to probe the heme stress response without confounding 
effects due to the toxicity of the parent molecule. 
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Figure 24. ‘3981-derivatives were identified with increased HssRS activation and decreased toxicity.  
(A) Systematic modification identified important characteristics of ‘3981, leading to identification of 
compound ‘7501 with increased ability to activate HssRS while lacking toxicity of the parent compound. 
(B) WT harboring phrt.xylE were treated with equivalent concentrations of ‘3981 and ‘7501. ‘7501 shows 
4-fold increased activity compared to the parent molecule. * denotes p < 0.05, ** denotes p < 0.0001. (C) 
Growth inhibition of ‘3981 and ‘7501 were determined. Whereas ‘3981 inhibits growth of WT bacteria, 
‘7501 lacks toxicity. 
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Figure 25. Activation of HssRS by S1 – S18 at 10 µM relative to ‘3981. 
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Figure 26. Activation of HssRS by S19 – S26 at 10 µM relative to ‘3981.  
S25 is excluded because data could not be obtained due to toxicity under the assay conditions. 
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Figure 27. ‘7501 activity is identical to ‘3981.  
(A) S. aureus was grown in the presence of ‘882, ‘3981, and ‘7501 and the absence of any exogenous heme 
source. While ‘882 activates heme biosynthesis, neither ‘3981 nor ‘7501 activate heme biosynthesis. 
Significance was determined in comparison with vehicle treatment. (B) S. aureus WT and DhemB 
harboring phrt.xylE were treated with increasing concentrations of ‘7501. No activation of HssRS was seen 
in the DhemB strain. Significance was determined in comparison with vehicle treatment of phrt.xylE. (C) 
WT harboring phrt.xylE were treated with heme, ‘882, or ‘7501 in an anaerobic environment. ‘7501 
activity is dependent upon intact respiration. * denotes p < 0.05, ** denotes p < 0.0001.  
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Table 11. General synthesis for SAR studies around ‘3981 structure. 
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A transposon screen identifies bacterial nitric oxide synthase as required for the 
heme stress response 
‘7501 exhibits increased activation of HssRS relative to ‘3981, therefore the 
ability of ‘7501 to adapt S. aureus to heme toxicity was tested (46, 47). Indeed, ‘7501 
adapts S. aureus to the toxic effects of heme. This result implies that HssRS activation 
was sufficient to upregulate HrtAB expression to enable the bacteria to subsequently cope 
with toxic concentrations of heme (Figure 28A). Using ‘7501-dependent heme adaptation 
as an assay platform, the Nebraska Transposon Mutant Library, consisting of 
approximately 2,000 strains of S. aureus with single, defined inactivating mutations, was 
screened to identify genes required for ‘7501 activity. Multiple genes were identified that 
are required for the ability of ‘7501 to activate the HssRS-HrtAB heme stress response 
(Table 12). Importantly, a number of these genes, including the gene encoding 
cytochrome protein Qox, are required for respiration, consistent with data presented in 
Figure 28 (Table 12). In addition, a number of the identified genes are in the pathway for 
production of NO directly through inactivation of bNOS, or for enzymes involved in 
pathways leading to NO formation (Figure 28B). This suggests that NO synthesis and the 
bacterial heme stress response are linked within S. aureus. Heme serves as a cofactor for 
bNOS implying the possibility of a functional link between these two systems.  
To verify that bNOS is required for the ability of S. aureus to adapt to heme 
stress, the nos::ermC mutation was transduced into S. aureus strain Newman (Dnos). As 
expected, interruption of bNOS led to decreased resistance to heme toxicity (Figure 29). 
Furthermore, this decreased resistance of Dnos to heme can be restored by providing a 
 111 
full length copy of nos in trans (Figure 29). Taken together, these results demonstrate that 
bNOS is required for adaptation to heme toxicity.  
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Figure 28. An adaptation screen uncovers the importance of nitric oxide to the heme stress response.  
(A) S. aureus strain USA300 JE2 was pretreated with ‘7501 followed by exposure to toxic concentrations 
of heme. ‘7501 adapts S. aureus to heme toxicity. (B) The Nebraska Transposon Mutant Library was 
screened to identify strains that could not be adapted to heme toxicity using ‘7501. Many strains disrupted 
in genes encoding nitric oxide synthesis proteins were identified (gray, bold). 
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Figure 29. Bacterial nitric oxide synthase is required for adaptation to heme toxicity.  
S. aureus WT harboring pOS1.Plgt, Dnos harboring pOS1.Plgt, and Dnos harboring plgt.nos were 
pretreated with heme followed by exposure to toxic concentrations of heme. WT is adapted to the toxic 
effects of heme, whereas Dnos is significantly impaired when treated with toxic concentrations of heme. 
This phenotype is complemented by addition of nos expressed in trans. Data shown are a representative 
sample. * denotes p < 0.05. 
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Table 12. Genes identified in ‘7501-induced adaptation to heme toxicity. 
Accession Number Gene name Gene description 
SAUSA300_0505 pdxT glutamine amidotransferase subunit PdxT 
SAUSA300_0191 ptsG PTS system, glucose-specific IIBC component domain protein 
SAUSA300_0561 - hypothetical protein 
SAUSA300_1271 - hydrolase-like protein 
SAUSA300_0616  putative Na+/H+ antiporter, MnhG component 
SAUSA300_2371 bioB biotin synthase 
SAUSA300_1458  glyoxalase family protein 
SAUSA300_0996 lpdA dihydrolipoamide dehydrogenase 
SAUSA300_1089 lspA lipoprotein signal peptidase 
SAUSA300_0759 gpmI phosphoglyceromutase 
SAUSA300_0539 ilvE branched-chain amino acid aminotransferase 
SAUSA300_0272  conserved hypothetical protein 
SAUSA300_1095 carA carbamoyl phosphate synthase small subunit 
SAUSA300_0633 fhuA ferrichrome transport ATP-binding protein fhuA 
SAUSA300_2438 sarU staphylococcal accessory regulator U 
SAUSA300_2395 - amino acid permease 
SAUSA300_0980 - hypothetical protein 
SAUSA300_1614 hemL glutamate-1-semialdehyde-2,1-aminomutase 
SAUSA300_0305 - formate/nitrite transporter family protein 
SAUSA300_1684 - hypothetical protein 
SAUSA300_0545 - hypothetical protein 
SAUSA300_0559  putative substrate--CoA ligase 
SAUSA300_2025 rsbU sigma-B regulation protein 
SAUSA300_1428 - hypothetical protein 
SAUSA300_0597 - putative endonuclease III 
SAUSA300_0847  conserved hypothetical protein 
SAUSA300_1948 - phi77 ORF069-like protein 
SAUSA300_1148 codY transcriptional repressor CodY 
SAUSA300_2309 hssS sensor histidine kinase (HssS) 
SAUSA300_1169 ftsK DNA translocase FtsK 
SAUSA300_2219 moaA molybdenum cofactor biosynthesis protein A 
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SAUSA300_1792 - hypothetical protein 
SAUSA300_0945 - isochorismate synthase family protein 
SAUSA300_2033 kdpB K+-transporting ATPase, B subunit 
SAUSA300_1842  transcriptional regulator, Fur family 
SAUSA300_0918 - diacylglycerol glucosyltransferase 
SAUSA300_1003  conserved hypothetical protein 
SAUSA300_2353  conserved hypothetical protein 
SAUSA300_0963 qoxA quinol oxidase, subunit II 
SAUSA300_1867  conserved hypothetical protein 
SAUSA300_0384 - hypothetical protein 
SAUSA300_1185 miaB (dimethylallyl)adenosine tRNA methylthiotransferase 
SAUSA300_1628 lysP lysine-specific permease 
SAUSA300_1895 NOS nitric oxide synthase oxygenase 
SAUSA300_2540  fructose-bisphosphate aldolase class-I 
SAUSA300_1558 mtnN 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase 
SAUSA300_2291 gltS sodium/glutamate symporter 
SAUSA300_0924 - sodium transport family protein 
SAUSA300_0958 - hypothetical protein 
SAUSA300_2312 mqo malate:quinone oxidoreductase 
SAUSA300_1182 - pyruvate ferredoxin oxidoreductase, alpha subunit 
SAUSA300_1866 vraS two-component sensor histidine kinase 
SAUSA300_1865 vraR DNA-binding response regulator 
SAUSA300_1544 lepA GTP-binding protein LepA 
SAUSA300_2345 nirD nitrite reductase [NAD(P)H], small subunit 
SAUSA300_2542 - putative AMP-binding enzyme 
SAUSA300_1092 pyrP uracil permease 
SAUSA300_0694  putative membrane protein 
SAUSA300_1648  putative NADP-dependent malic enzyme 
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bNOS contributes to heme sensing and detoxification independent of hrtAB 
The mechanism by which bNOS protects S. aureus from heme toxicity could be 
due to activation of HssRS or general protection from heme toxicity through an HssRS-
independent mechanism. To determine if bNOS contributes to heme sensing through 
HssRS, WT and Dnos were treated with either vehicle, heme, or ‘7501 and the response 
of the hrt reporter was measured as described above. Interestingly, Dnos exhibits a 
significant decrease in activation of the hrt promoter; however, the magnitude of this 
change does not fully account for the differences in response to heme (Figure 30A). 
Based on these observations, we hypothesized that in addition to an involvement in 
sensing heme toxicity, bNOS is involved in resisting heme toxicity in a mechanism 
distinct from HssRS activity. To test this hypothesis, an hrtB/bNOS double mutant was 
constructed to determine if this strain is more sensitive to heme toxicity than inactivation 
of hrtB alone. A strain lacking the heme efflux system (DhrtB) is more resistant to heme 
toxicity than an hrtB/bNOS double mutant, implicating bNOS in protecting S. aureus 
from heme toxicity independently of hrtB (Figure 30B). Taken together, these data 
suggest that bNOS both affects sensing of heme by HssRS and protects S. aureus from 
heme toxicity through a mechanism distinct from the actions of HssRS and HrtAB. 
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Figure 30. Bacterial nitric oxide synthase affects heme sensing and protects S. aureus from heme 
toxicity independently of hrtAB.  
(A) To determine if bNOS contributes to heme sensing, S. aureus WT and Dbnos harboring phrt.xylE were 
treated with heme. The Dbnos strain shows a significant decrease in the ability to sense heme, suggesting 
bNOS plays a role in heme sensing in S. aureus. (B) To determine if bNOS contributes to protection from 
heme toxicity independent of HssRS/HrtAB, strains WT, Dbnos, DhrtB, Dbnos/DhrtB were grown in the 
presence of low concentrations of heme. Strain Dbnos/DhrtB has a significant growth defect compared to 
DhrtB suggesting bNOS contributes to the protection from heme toxicity independent of HssRS/HrtAB. * 
denotes p < 0.05, ** denotes p < 0.0001. 
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CONCLUSIONS 
 
Maintaining correct heme homeostasis is crucial for the survival of bacterial 
pathogens within the host (46, 131). Heme is a required molecule for many processes 
within the cell; however, it is also toxic to the organism. This concept has been termed 
the “heme paradox” (131). Therefore, being able to sense and respond to increased heme 
levels is vital for organisms to survive in the diverse environments experienced within the 
host. Understanding the mechanisms by which these bacterial pathogens sense and 
respond to heme stress has the potential to uncover novel targets for therapeutic 
development, as altering the ability of S. aureus to sense heme affects virulence of this 
organism (46).  
Understanding the specific requirements of two-component system activation 
remains a challenge (40). In order to further our understanding of the heme stress 
response and the mechanisms of HssRS activation, this work utilized a small molecule 
activator of the heme sensing system. Previously identified small molecule activators of 
HssRS have multiple activities within the cell, and have provided a more thorough 
understanding of the mechanisms behind heme homeostasis within the bacterial cell (47, 
49). Consistent with this, here we report that ‘3981 is both toxic to S. aureus and 
activates HssRS in a respiration-dependent manner (Figure 21 and Figure 23). Structure 
activity relationship studies have separated these activities (Figure 24), thereby providing 
‘3981-derivatives that lack toxicity, and thus enhancing the ability of this scaffold to 
interrogate the heme stress response. 
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Heme is the canonical activator of HssS in S. aureus (44, 46, 47). Small molecule 
activators provide an opportunity to interrogate two-component system activation. 
Importantly, ‘3981 does not induce heme accumulation within S. aureus (Figure 22). 
These data support the possibility that there may be multiple ligands required for HssS 
activation. Activation by multiple ligands is not unprecedented. In Mycobacterium 
tuberculosis, DosS and DosT are histidine kinases that sense heme and their activity is 
modulated by other ligands, including CO, NO, and O2 (132). This leads to the exciting 
hypothesis that perhaps HssS senses heme in complex with another intracellular molecule 
to modulate the response to heme stress.  
Previous work has shown the importance of bNOS in survival in the host, as well 
as resistance to various antibiotics and oxidative stress (123). The importance of 
endogenous nitric oxide production has been demonstrated in numerous organisms, 
including the pathogens S. aureus and B. anthracis (123). Taken together, bNOS has 
been proposed as a viable antibacterial target (125). Consistent with this, utilizing ‘3981 
has identified another role for bNOS in S. aureus, specifically in resistance to heme 
stress. Although bNOS contributes slightly to heme sensing, it plays a crucial role in 
resisting heme stress independently of the HssRS-HrtAB heme stress response (Figure 
30). Heme induces significant oxidative stress in S. aureus (127). It is likely that bNOS 
protects S. aureus from the oxidative stress imposed by heme, as bNOS protects bacteria 
from oxidative stress. Targeting bNOS for antibiotic development has the potential to 
affect a number of systems within the bacteria, and therefore significantly impact 
virulence of this pathogen. 
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Overall, this work has provided a unique look into the heme stress response in S. 
aureus. SAR separated two phenotypes induced by ‘3981, ultimately providing probes 
with significantly increased ability to activate the bacterial heme stress response. In 
addition, these probes activate the heme sensing system independently of heme 
accumulation, suggesting that heme may not be the only molecule required for HssRS 
activation. Finally, these probes have identified bNOS as required for the heme stress 
response, uncovering another important role of nitric oxide synthesis in bacterial 
pathogens and highlighting bNOS as a target for antibacterial development.  
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CHAPTER V. SUMMARY AND SIGNIFICANCE 
 
S. aureus is a major human pathogen that causes significant morbidity and 
mortality worldwide (2-4, 91). Furthermore, the levels of antibiotic resistance in bacterial 
pathogens is increasing. It is estimated that if the antimicrobial resistance problem is not 
tackled, it will result in over $100 trillion in losses by 2050, and cause over 10 million 
deaths annually (133). Understanding the pathogenesis of bacterial pathogens is vital to 
our continued treatment of infectious agents. The work presented in Chapters II through 
IV deepen our understanding of various aspects of bacterial survival and treatment in the 
host.  
 
UNDERSTANDING HEME SENSING AND DETOXIFICATION IN S. AUREUS 
Understanding mechanisms by which bacteria respond to their environment is 
crucial for understanding bacterial physiology and will aid in the identification of 
potential therapeutic targets. During infection of the host, bacteria experience to a large 
array of stressors. Two-component systems are a major mechanism by which bacteria 
sense and respond to their environment (38-41). Specifically, bacteria require proper 
heme homeostasis to survive and cause disease. Although required, heme is also toxic to 
the bacteria. S. aureus encodes the heme sensing system (HssRS) in order to sense and 
respond to heme toxicity within the host. The specific mechanisms by which heme is 
sensed and whether it physically interacts with HssS remains unknown. 
New tools are needed to interrogate two-component system signaling (38, 80, 90). 
Many of the current methods require a directed approach to select residues to mutate to 
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determine their effect on two-component system function. Chapter II describes the 
development of a suicide strain to interrogate two-component systems. The unbiased 
selection strategy was applied to the S. aureus HssRS two-component system. 
Preliminary results have identified numerous mutations that decrease HssRS function. 
These data suggest that endogenous and exogenous heme are sensed through a similar 
mechanism. Upon saturation of this system, a stronger understanding of the residues 
required for HssRS and Phrt function will be gained. The success of the suicide strain 
strategy suggests it can be used to interrogate additional two-component systems, which 
will further our understanding of the mechanisms by which numerous pathogens sense 
and respond to their environment. Finally, the suicide strain can be utilized to identify 
small molecule targets in bacterial pathogens, the topic of Chapter III. 
Chapter IV utilized a second activator of HssRS to further interrogate the 
mechanisms of heme sensing and detoxification. Importantly, SAR studies on molecule 
‘3981 was able to separate two phenotypes induced by the parent molecule: HssRS 
activation and toxicity. Based upon these data, a non-toxic and more potent HssRS 
activator, ‘7501, was synthesized. Using a genetic screen, a role for bNOS was identified 
in resisting heme toxicity. Nitric oxide synthesis contributes to HssRS activation, as well 
as detoxification through a mechanism independent of HssRS and HrtAB. Heme toxicity 
is induced in bacterial cells through production of significant oxidative stress (127). 
bNOS has been previously reported to increase resistance to oxidative stress (125, 134). 
In keeping with this, it is possible that bNOS protects S. aureus from heme toxicity 
through increasing resistance to oxidative stress. Alternatively, bNOS requires heme as a 
cofactor and could serve as a heme sink within bacterial cells, thereby reducing free heme 
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in the cell that contributes to toxicity (30, 134, 135). Consistent with the work presented 
in Chapter IV, there are likely many mechanisms in place for S. aureus and other 
pathogens to resist heme toxicity. As heme sensing and detoxification systems are 
conserved across numerous pathogens, the data presented in Chapters II and IV have 
furthered our understanding of the mechanisms by which bacteria sense and respond to 
heme. 
 
DEVELOPING PROBES TARGETING HEME BIOSYNTHESIS 
Heme biosynthesis occurs in organisms from all kingdoms of life. Recently, it 
was discovered that Gram-positive bacteria utilize a noncanonical pathway to synthesize 
this essential cofactor, stimulating interest in development of therapeutics targeting heme 
biosynthesis to treat bacterial infections. In addition, regulation of this pathway is not 
well understood, highlighting the need for validated probes to interrogate heme 
biosynthesis. Previously small molecule activators of HssRS were identified in order to 
interrogate heme homeostasis in S. aureus. Small molecule ‘882 increases endogenous 
heme biosynthesis, although the mechanism by which ‘882 functions remained unknown 
(47, 49). Chapter III describes the use of a Phrt driven suicide strain as a strategy to 
identify the target of ‘882. Analysis of suppressor mutants resistant to ‘882, in 
combination with follow-up studies, identified that ‘882 activates HemY, a 
coproporphyrinogen oxidase specific to Gram-positive bacteria. 
Small molecule activators are rare, with only a handful identified to date (116). 
Many groups focus efforts on enzyme inhibition through binding of and inhibiting the 
active site of the enzyme. Active sites are often conserved across classes of enzymes and 
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well characterized, aiding in the process of targeting these sites. Enzyme activation 
occurs through a different mechanism, one of the most common of which is through 
small molecule-binding to an allosteric site (116). In keeping with this, enzymes that 
contain allosteric sites may have evolved such a site for natural regulation of the enzyme 
(116). Therefore, identification of small molecule activators provides imporant insight 
into enzyme regulation. With regards to heme biosynthesis, the regulation of the pathway 
remains largely unknown (21, 136, 137). Taken together, insights gained utilizing ‘882 
will aid in elucidating regulation of heme biosynthesis in Gram-positive bacteria. 
Small molecule activators also have numerous properties that make them ideal 
therapeutics (116). As described above, allosteric sites are less well conserved across 
classes of enzymes than is the conservation of active sites, thus limiting off-target effects 
of small molecule activators that bind allosteric sites. In addition, inhibitors often require 
the ability to inhibit an enzyme by 90% to induce a strong phenotype (116). In contrast, 
small molecule activators can induce significant phenotypes with small modulations in 
enzyme activity, suggesting that SAR studies that leads to synthesis of derivatives with 
small increases in activity may lead to dramatic increases in therapeutic effects (116). An 
example of the success of enzyme activation in therapeutics can be seen in glucokinase 
activators, which are now used in clinics to treat diabetes (116, 117).  
PDT involves the use of a photosensitizer in the presence of light to induce cell 
death (16). As a therapeutic strategy, PDT has been successful in the treatment of 
numerous diseases. To date, the application of PDT has been limited against bacterial 
infections as the only FDA approved therapy consists of ALA, an early precursor in heme 
biosynthesis. With the identification of the noncanonical heme biosynthesis pathway 
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utilized by Gram-positive bacteria, targeting bacterial heme biosynthesis in combination 
with light is a promising strategy. ‘882 specifically activates HemY from Gram-positive 
bacteria, and does not activate HemY from H. sapiens. The product of HemY from 
Gram-positive bacteria is CPIII, a well characterized photosensitizer (16, 61, 100). 
Chapter III describes the successful application of ‘882-PDT against Gram-positive 
bacteria in vitro and in vivo. Taken together, the identification of ‘882 as a small 
molecule activator of HemY will allow for further interrogation of the regulation of heme 
biosynthesis, as well as providing proof-of-concept that HemY activation in combination 
with light is a viable therapeutic strategy to treat infectious diseases. 
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CHAPTER VI. FUTURE DIRECTIONS 
 
To continue the battle against bacterial pathogens, a more complete understanding 
of bacterial physiology is necessary to identify novel therapeutic targets. The work 
presented in Chapters II-IV provide a more in depth understanding of various aspects of 
bacterial physiology, disease, and treatment. Nonetheless, a number of questions remain 
to be addressed. 
 
UNDERSTANDING MECHANISMS OF HEME RESISTANCE: 
INTERROGATE THE STRUCTURE AND FUNCTION OF HSSRS.  
Chapter II describes the development and verification of a suicide strain selection 
strategy as a method to interrogate two-component system structure and function. The 
use of the suicide strain has led to the identification of numerous residues required for 
HssRS and Phrt function, although future work remains to obtain a full understanding of 
heme resistance in S. aureus. 
 
Saturate the suicide strain selection. 
Although a number of residues have been identified, the work presented in 
Chapter II is not a complete list of residues required for HssRS activation. Continued 
efforts should be focused on further selection until adequate coverage has been obtained, 
ideally when no new residues are being identified in the selections. Upon completion, 
there will be many opportunities to further the understanding of the mechanism of heme 
sensing in S. aureus.  
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First, mutations in HssRS should be interrogated to determine their effects on 
protein expression through immunoblots as described in Chapter II. Those mutations that 
do not affect expression should be further interrogated to determine potential effects on 
autophosphorylation, phosphotransfer from HssS to HssR, or DNA-binding of HssR to 
Phrt. Methods for interrogating mutations in these systems have been previously described 
(44, 93). Mutations in Phrt should be interrogated to determine their effect on HssR 
binding. Completion of these studies will classify the mutations as described in Figure 8. 
Furthermore, since exogenous and endogenous heme are utilized in the suicide strain 
selections, insight into the mechanism by which these two heme sinks are sensed can be 
interrogated. Once the selections are completed, it is possible that the same residues will 
be identified with both ligands, suggesting that the two heme sinks are sensed through a 
similar mechanism. Interrogation of mutations specific to each should be performed to 
determine specific requirements of sensing each heme source. 
Overall, identifying these residues aids in the understanding of two-component 
system signaling. First, identifying residues required for function provides an insight into 
the impact of each domain in HssRS function. The number of mutations identified in 
each domain will provide an understanding of the sensitivity of each domain to 
modulations in structure. For instance, current data suggests that mutations in membrane 
spanning domains of the histidine kinase are not required for function, as no mutations 
have been identified in these regions. In addition, identifying mutations in an unbiased 
manner allows for a functional analysis of each domain, allowing for further 
characterization of known domains. Finally, specificity of two-component signaling is 
not fully understood (41). Sequence analysis has shown that two-component systems 
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share high sequence homology, however, specificity for their cognate partners is retained. 
Identifying residues required for interaction of the histidine kinase and the response 
regulator can be further interrogated for their importance in providing specificity in the 
signaling pathway. Taken together, using an unbiased selection strategy provides a tool to 
interrogate two-component system function. 
 
Obtain a crystal structure of HssR and HssS. 
In addition to identifying residues, understanding the structural impact of these 
mutations is important to dissect two-component system structure and function. 
Therefore, HssS and HssR should be crystalized. Mapping mutations identified in the 
suicide strain selection will give a more complete understanding of their structural 
impact, combined with the functional impacts described in Section 1a. The completion of 
these studies will allow for a relationship between structural domains and their functional 
impact on HssRS activity.  
 
Apply suicide strain strategy to other two-component systems. 
The successful application of a suicide strain to HssRS signaling suggests this 
method can be adapted to study other two-component systems. S. aureus has sixteen two-
component systems that should be interrogated through use of a suicide strain. As 
discussed in Chapter II, the mechanisms of signaling in these systems remains to be 
elucidated. Therefore, applying a suicide strain selection strategy to each two-component 
system has the potential to significantly increase our understanding of multiple signaling 
networks in S. aureus. 
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The use of a suicide strain is not limited to S. aureus. Many bacterial pathogens 
encode heme sensing two-component system (44, 46, 81, 93, 131, 138). A suicide 
selection strategy should be applied to each of these organisms. For example, B. 
anthracis, also encodes hssRS/hrtAB that shares high similarity with S. aureus 
hssRS/hrtAB. Comparing the structural and functional effects of mutations in HssRS in 
these two organisms will identify conserved determinants of heme sensing. Furthermore, 
utilizing a less similar heme sensing system, one can identify shared features required or 
specific to two-component systems from more diverse organisms. Taken together, the 
completion of these studies will provide insights into heme sensing by two-component 
systems across numerous medically relevant pathogens.  
 
Dissect two-component system specificity. 
The suicide selection should be adapted to dissect specificity of two-component 
system signaling as well. Two-component systems that sense diverse stimuli often share 
high sequence similarity. Numerous studies have attempted to understand how signaling 
specificity is conserved (41, 81, 139). In addition, there are many examples of cross-talk 
and cross-regulation among multiple two-component systems in which a histidine kinase 
or response regulator interacts with a component from a separate two-component system 
(38, 40, 41, 81). The suicide strain should be adapted to study cross-talk and cross-
regulation. As an example, B. anthracis encodes a two-component system, HitRS, that 
exhibits cross-regulation with HssRS (81). Specific activators of both histidine kinases 
have been identified (81). Application of a Phrt driven suicide strain using a specific 
activator of HitRS will identify residues required for HitRS-HssRS interactions. 
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Similarly, application of a Phit driven suicide strain with an activator of HssRS will 
identify residues required for cross-regulation from HitRS to HssRS. Taken together, this 
work will identify features that provide specificity for two-component system 
interactions, and provide a stronger understanding of the mechanisms of cross-talk and 
cross-regulation. 
 
Identify the ligands of two-component systems. 
Identifying ligands of two-component systems remains a significant challenge 
(40). Heme is the canonical activator of HssS, however, a direct interaction has not been 
shown (44, 46, 135). Therefore, efforts should focus on identifying the ligand for HssS, 
and determine whether heme directly activates HssS. Previous methods to interrogate 
ligand-histidine kinase interactions should be performed, such as reconstitution of the 
recombinant HssS in liposomes and utilization of membrane vesicles from strains 
overexpressing HssS (42, 83). Autophosphorylation of HssS can be monitored in the 
presence of potential ligands to determine their effect on HssS. Heme should be utilized 
to determine if heme directly activates HssS. As described in Chapter IV, DosST from M. 
tuberculosis binds heme in combination with nitric oxide or carbon monoxide (132). 
Consistent with conclusions from Chapter IV, it is possible that nitric oxide may bind 
HssS as well. Therefore, nitric oxide and nitric oxide in combination with heme should be 
interrogated to determine their impact on HssS activation.  
Finally, the suicide strain strategy should be utilized to identify additional genetic 
requirements of HssS activation. Utilizing the Phrt driven suicide strain, heme resistant 
isolates should be identified that lack mutations in hssRS/Phrt, as was performed with ‘882 
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in Chapter III. This will identify genetic elements required for heme-induced HssS 
activation. Pathway analysis of the mutations identified will provide insight into potential 
ligands of HssS. Molecules identified in this analysis should then be tested in the 
liposome and membrane vesicle phosphorylation experiments described above.  
 
Determine mechanism of ‘3981-induced HssRS activation. 
The canonical mechanism by which S. aureus alleviates heme toxicity is through 
activation of HssRS to increase hrtAB expression (44, 46). The work described in 
Chapter IV has identified bacterial nitric oxide production as a second mechanism of 
heme resistance, which contributes to heme sensing as well as detoxification. Further 
studies should investigate the mechanisms of ‘3981-induced adaptation to heme toxicity. 
 
Identify the subcellular target of ‘3981 
In order to obtain a full understanding of ‘3981-induced HssRS activation, the 
subcellular target of ‘3981 should be identified. Preliminary SAR studies presented in 
Chapter IV begin to determine molecular features required for ‘3981-induced HssRS 
activation. A series of SAR studies described in Chapter IV are ongoing and have 
identified structural elements necessary for ‘3981-induced activity. A subset of ‘3981 
derivatives are shown in Table 11. Based upon these data and future SAR studies, 
biochemical and photoactive linkers should be attached to locations that do not affect 
‘3981 activity, thereby creating live probes that bind the target(s) of ‘3981. Dead probes 
should also be synthesized that contain molecular features that inhibit the ability of ‘3981 
to activate HssRS. Using bacterial cell lysates, a series of pull down experiments should 
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be performed. Proteins identified with the live probe that are not present in the dead 
probe experiments should be identified as potential targets. This approach should isolate 
targets that physically interact with ‘3981-derived probes. Confirmatory experiments 
should prioritize proteins with the highest abundance in the pull down experiments. The 
potential interaction with ‘3981-derived probes should be interrogated through a series of 
genetic and biochemical approaches that should be selected based upon the proteins 
identified.  
Preliminary studies have tested ‘3981 in the hrtAB::relE strain to identify 
mutations providing resistance to ‘3981. Interestingly, ‘3981 did not induce growth 
arrest, suggesting the potency of ‘3981 is insufficient to induce sufficient relE expression 
to halt growth of the bacteria. Future studies should attempt to modify the suicide strain 
to induce increased levels of toxicity. For example, more copies of relE could be 
incorporated, or multiple different toxins could be incorporated into a single strain. ‘3981 
should be tested using the new suicide strain to identify strains resistant to ‘3981 that lack 
mutations in HssRS/Phrt (47). Taken together the completion of these studies will provide 
a characterization of binding partners of ‘3981, and mechanisms of resistance to ‘3981-
induced HssRS activation. Furthermore, the analysis of these data will provide the 
foundation for identifying the target of ‘3981. 
 
  
 133 
Determine the mechanism by which bNOS alters heme detoxification. 
The results presented in Chapter IV suggest that bacterial nitric oxide is important 
in heme sensing by HssRS, as well as detoxification through a mechanism distinct from 
HssRS/HrtAB. To interrogate the role of nitric oxide in HssRS activation, future studies 
should interrogate the possibility of nitric oxide, or a nitric oxide-heme complex in 
binding HssS. In addition, future studies should determine the mechanism by which 
bNOS contributes to resisting heme stress independent of HssRS/HrtAB. Previously it 
has been shown that bNOS provides resistance to oxidative stress (122, 125, 134, 140). 
Consistent with this, the primary mechanism by which heme induces toxicity in S. aureus 
is through the production of oxidative stress (127). Therefore, future studies should 
address the hypothesis that bNOS protects S. aureus from the oxidative stress induced by 
heme. Alternatively, bNOS may protect S. aureus from heme induced toxicity through 
other mechanisms. bNOS utilizes heme as a cofactor (134). Future studies should 
interrogate whether bNOS can serve as a heme sink within the cell, thereby decreasing 
free heme and therefore reducing heme-induced toxicity. Taken together, completion of 
these studies will provide the mechanism by which bNOS affects heme sensing and 
detoxification. 
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DEVELOPMENT OF PROBES AND LIGHT-BASED THERAPEUTICS TARGETING HEME 
BIOSYNTHESIS 
 
DEVELOP HEMY ACTIVATORS BASED UPON THE ‘882-SCAFFOLD. 
Chapter III describes the identification of HemY as the target of ‘882. ‘882 represents a 
probe for interrogation of heme biosynthesis as well as a potential therapeutic. 
 
Advance SAR studies around ‘882. 
SAR studies presented in previous work and Chapter III have defined features of 
‘882 that are required for activity (49). Based upon these SAR data, a new series of 
compounds should be developed to further characterize ‘882-induced HemY activation. 
These derivatives should be tested in the HemY activity assay for in vitro activity and the 
XylE activity assay for in vivo activity, as shown in Table 8. 
 
Determine the mechanism of ‘882-induced activation of HemY. 
‘882 has been shown to directly interact with and activate HemY from Gram-
positive bacteria. A functional domain has been identified that is required for ‘882-
induced activation, however, whether ‘882 directly binds to the identified fictional 
domain remains unknown. To date, many attempts have been made to obtain a crystal 
structure of ‘882 bound to HemY. The S. aureus HemY-‘882 complex has not 
crystalized, and the structures obtained from B. subtilis HemY have a set of flexible loops 
adjacent to the functional domain identified in Chapter III, preventing the successful 
determination of the ‘882-HemY structure. Importantly, previously published structures 
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of HemY are also incomplete in this region (36, 115). Clearly this is a dynamic part of 
the enzyme, consistent with it playing a role in enzyme activation. Future studies should 
continue crystallization efforts in order to obtain a structural understanding of ‘882-
induced HemY activation. As ‘882 activates HemY from a variety of Gram-positive 
bacteria, HemY from other species should be purified, and crystallization efforts should 
include these enzymes as well.  
 
Probe heme biosynthesis with ‘882 to understand regulation of this pathway. 
The identification of a small molecule that activates HemY may not be a random 
occurrence. Interestingly, HemY activity is increased to a similar extent by in vitro 
interactions with HemQ, the terminal pathway enzyme in this heme synthesis pathway 
(34). This suggests that the interaction of HemY with ‘882 may represent an 
inappropriate hijacking of a normal in vivo regulatory mechanism. Future work should 
attempt to identify intracellular molecules that may activate HemY. Lysates from S. 
aureus should be fractionated and screened in the Phrt.lux assay as previously described 
(47). Efforts should then be focused on identifying specific molecules that activate 
HssRS. Compounds confirmed to activate HssRS should then be tested in the HemY 
activity assay to determine their direct effect on HemY activity.  
Regulation of heme biosynthesis remains largely unknown (21). ‘882 leads to an 
accumulation of CPIII in bacterial cells. By modulating HemY activity, effects of 
increased CPIII production can be characterized through transcriptional and translational 
changes of the enzymes involved in heme biosynthesis, which will elucidate potential 
regulatory mechanisms in S. aureus heme biosynthesis. In addition, HemY activity 
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should be tested in the presence of precursors and products in the heme biosynthesis 
pathway to determine if HemY is modulated through feedback or feedforward regulation. 
Finally, it has previously been shown that in vitro addition of HemQ increases HemY 
activity (24, 32, 34). This suggests that HemY may interact with HemQ. Therefore, the 
HemY-HemQ interaction may be required for regulation of HemY activity. Therefore, 
molecules identified in the screen described above as well as intermediates in the heme 
biosynthesis pathway should also be tested in the presence of HemQ. Taken together, the 
completion of these studies will provide insights into the regulation of heme biosynthesis 
in Gram-positive bacteria. 
 
THERAPEUTIC APPLICATION OF ‘882-BASED ANTIMICROBIALS. 
Current antimicrobial PDT is limited due to non-specific effects of ALA, the only 
FDA approved photosensitizer (16). ‘882-PDT has been validated as a potential bacterial 
specific therapeutic strategy in Chapter III. Future studies should continue to develop 
‘882-based therapeutics for treatment of infectious diseases. 
 
Optimize application of the ‘882-based therapeutics. 
In order to develop ‘882-based therapeutics, numerous studies should be 
performed. First, species that are responsive to ‘882 should be determined. HemY from 
addition Gram-positive bacterial species should be purified and tested for ‘882-induced 
activation as discussed in Chapter III. Based upon the results from this analysis, the range 
of species that may be sensitive to ‘882-PDT can be determined. Second, the SAR studies 
presented in Chapter III in combination with future studies should be utilized to design 
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superior ‘882 derivatives for in vivo testing. The most active probes should be tested for 
toxicity. In addition, drug metabolism and pharmacokinetic studies should be performed 
to identify probes that have favorable properties for in vivo testing. Finally, devices to 
deliver light to the site of infection should be optimized. The data presented in Chapter III 
utilizes 2.5 J/cm2 of blue-light. Importantly, this dose of light is significantly lower than 
has previously been utilized in murine models of S. aureus infection treated with ALA-
PDT (100). Limiting the intensity of light exposure decreases the possibility of off-target 
effects on mammalian skin. Taken together, optimizing ‘882-derivatives for therapeutic 
development, and optimizing light delivery is important in development of ‘882-based 
PDT. 
 
Determine resistance frequency and mechanisms of resistance to ‘882-PDT. 
An important limitation of current antimicrobial therapies is the development of 
resistance to antibiotics. To further characterize ‘882 as a potential therapeutic, the 
resistance frequency and the mechanisms of resistance should be determined. This will 
further define the utility of ‘882-PDT as a potential therapeutic option in treating 
infectious diseases. Researchers have attempted to determine the frequency of bacterial 
resistance to current PDT strategies. Interestingly, bacteria resistant to PDT have not been 
identified (16, 20, 141). Identifying the frequency and mechanisms of resistance to ‘882-
PDT will characterize the long-term efficacy of ‘882-PDT as a therapeutic strategy. 
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Develop small molecule activators of HemY outside of Gram-positive organisms. 
The successful application of ‘882 to modulate heme biosynthesis opens the doors 
for applications beyond Gram-positive bacteria. H. sapiens and Gram-negative Bactria 
encode HemY enzymes that serve as protoporphyrinogen oxidases, which although 
similar, are structurally distinct from HemY from Gram-positive organisms. Importantly, 
deficiencies of HemY in H. sapiens results in a disease known as variegate porphyria 
(137, 142). Upon obtaining a structure of the HemY-‘882 complex, structural 
relationships between HemY from Gram-positive bacteria, HemY from Gram-negative 
bacteria, and HemY from H. sapiens should be determined. Ultimately, this analysis will 
provide insight into developing small molecules that target HemY from H. sapiens and 
Gram-negative bacteria. Molecules targeting HemY from H. sapiens could provide 
insights into treatments for variegate porphyria. The success of ‘882-PDT in treating 
Gram-positive bacterial infections provides proof-of-concept that activation of porphyrin 
production induces toxicity in the presence of light. Therefore, small molecules that 
activate HemY from Gram-negative bacteria will allow for the development of small 
molecule based PDT strategies to treat Gram-negative bacterial infections. Taken 
together, future studies should focus on expanding the application of small molecule 
HemY activators.  
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